JPH0119364B2 - - Google Patents
Info
- Publication number
- JPH0119364B2 JPH0119364B2 JP13530083A JP13530083A JPH0119364B2 JP H0119364 B2 JPH0119364 B2 JP H0119364B2 JP 13530083 A JP13530083 A JP 13530083A JP 13530083 A JP13530083 A JP 13530083A JP H0119364 B2 JPH0119364 B2 JP H0119364B2
- Authority
- JP
- Japan
- Prior art keywords
- triamterene
- hydrochlorothiazide
- component
- granules
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 claims description 112
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical group NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims description 68
- 229960001288 triamterene Drugs 0.000 claims description 66
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 62
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 60
- 239000008187 granular material Substances 0.000 claims description 57
- 239000002245 particle Substances 0.000 claims description 33
- 239000002775 capsule Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 27
- 239000007884 disintegrant Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 208000019025 Hypokalemia Diseases 0.000 claims description 15
- 208000024896 potassium deficiency disease Diseases 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 11
- 239000002934 diuretic Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 claims description 9
- 230000001882 diuretic effect Effects 0.000 claims description 8
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 6
- 230000000396 hypokalemic effect Effects 0.000 claims description 6
- 239000005414 inactive ingredient Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 239000008240 homogeneous mixture Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 31
- 239000004480 active ingredient Substances 0.000 description 28
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 22
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 21
- 238000009472 formulation Methods 0.000 description 20
- 235000019359 magnesium stearate Nutrition 0.000 description 15
- XZRKEDHJXXLVSK-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;6-phenylpteridine-2,4,7-triamine Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 XZRKEDHJXXLVSK-UHFFFAOYSA-N 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 9
- 239000002131 composite material Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000003801 milling Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229940082226 hydrochlorothiazide 50 mg Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- HZNXXJPJGJLVDJ-UHFFFAOYSA-N 2-n,2-n-dimethyl-6-phenylpteridine-2,4,7-triamine Chemical compound NC1=NC2=NC(N(C)C)=NC(N)=C2N=C1C1=CC=CC=C1 HZNXXJPJGJLVDJ-UHFFFAOYSA-N 0.000 description 1
- IPBFJYXRBREMIH-UHFFFAOYSA-N 2-n,4-n,7-n,7-n-tetramethyl-6-phenylpteridine-2,4,7-triamine Chemical compound CN(C)C1=NC2=NC(NC)=NC(NC)=C2N=C1C1=CC=CC=C1 IPBFJYXRBREMIH-UHFFFAOYSA-N 0.000 description 1
- GXCOXYQKWSWCGG-UHFFFAOYSA-N 6-(2-methylphenyl)pteridine-2,4,7-triamine Chemical compound CC1=CC=CC=C1C1=NC2=C(N)N=C(N)N=C2N=C1N GXCOXYQKWSWCGG-UHFFFAOYSA-N 0.000 description 1
- QWRHUIKWHMRIRM-UHFFFAOYSA-N 6-(3-methoxyphenyl)pteridine-2,4,7-triamine Chemical compound COC1=CC=CC(C=2C(=NC3=NC(N)=NC(N)=C3N=2)N)=C1 QWRHUIKWHMRIRM-UHFFFAOYSA-N 0.000 description 1
- FOOUSUZUPXOHBJ-UHFFFAOYSA-N 6-(4-ethoxyphenyl)pteridine-2,4,7-triamine Chemical compound C1=CC(OCC)=CC=C1C1=NC2=C(N)N=C(N)N=C2N=C1N FOOUSUZUPXOHBJ-UHFFFAOYSA-N 0.000 description 1
- NLVXZEDUAGHDTQ-UHFFFAOYSA-N 6-(4-fluorophenyl)pteridine-2,4,7-triamine Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=C(F)C=C1 NLVXZEDUAGHDTQ-UHFFFAOYSA-N 0.000 description 1
- -1 94/6 weight ratio) Chemical compound 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UGLZTFAGJYBEIZ-UHFFFAOYSA-N [4-(2,4,7-triaminopteridin-6-yl)phenyl] hydrogen sulfate Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=C(OS(O)(=O)=O)C=C1 UGLZTFAGJYBEIZ-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ORXJMBXYSGGCHG-UHFFFAOYSA-N dimethyl 2-methoxypropanedioate Chemical compound COC(=O)C(OC)C(=O)OC ORXJMBXYSGGCHG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 231100000673 doseâresponse relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960003739 methyclothiazide Drugs 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003195 pteridines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
çºæã®åé
æ¬çºæã¯æå¹ãªå©å°¿äœçšåã³éå§äœçšãæãã
äœã«ãªãŠã è¡çãæå¶åã¯å埩ãããæ°èŠå»è¬çµ
æç©ã«é¢ãããæŽã«è©³è¿°ããã°ãæ¬çºæã¯ããã
ã¯ãããã¢ãžãïŒïŒâã¯ããâïŒïŒïŒâãžããã
â2HâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãžãâïŒâ
ã¹ã«ãã³ã¢ããâïŒïŒïŒâãžãªãã·ãïŒåã³ããª
ã¢ã ãã¬ã³ïŒïŒïŒïŒïŒïŒâããªã¢ããâïŒâããš
ãã«ãããªãžã³ïŒãå«ã¿ãäž¡æåã®åäžãããã€
ãªã¢ãã€ã©ããªãã€ã瀺ãæ°èŠå»è¬çµæç©ãæäŸ
ãããã®ã§ãããæŽã«ãäœã«ãªãŠã è¡å¯äœçšãé²
æ¢åã¯æé€ããªãããå©å°¿åã³éå§è€åè¬ã䜿çš
ããæäžããæ¹è¯ãããæ°èŠæ¹æ³ãæäŸãããæŽ
ã«ãæ¬çºæã¯çžå¯Ÿççæ°Žæ§åã³èŠªæ°Žæ§åã³ïŒåã¯
ççåŠç液äœãžã®æº¶è§£æ§ã«ãããŠçžäºã«èããç°
ãªãïŒçš®ä»¥äžã®æ²»æ§æåãå«ãå»è¬çµæç©ãäžè¬
çã«è£œé ããæ°èŠæ¹æ³ãæäŸãããã®ã§ããã åŸæ¥æè¡ æŽ»æ§æåãïŒçš®ä»¥äžå«ãå»è¬çµæç©ã補é ãã
ããšã¯å»åŠã«ãããŠäžè¬çã«èŠæ±ãããŠæ¥ããã
çŸåšãèŠæ±ãããŠããã屡ã ãæåãåã«æ··åã
ãŠå°é£ãªãå®å®æ§åã³ãã€ãªã¢ãã€ã©ããªãã€ã
ä¿æããããšãã§ãããä»ã®å Žåã«ã¯ããããã
ã®æŽ»æ§æåã¯ãçžäºã«åå¿ããåºäœè£œå€ã«ãããŠ
ããå®å®æ§ã®åé¡ãèµ·ããå¯èœæ§ãæããç¹æ®ã®
調補æ段ãå¿ èŠãšããããŸããä»ã®å Žåã«ã¯ãé
å€åã¯ã«ãã»ã«å€ã«ããå Žåã«çµæç©ã«å«ãŸãã
ã®ãæ®éã§ãããçš®ã ã®ãè¬åŠçã«èš±å®¹ãããäž
掻æ§æåã«ãã€ãŠãè€åå»è¬è£œå€äžã®æŽ»æ§æåã®
ãã€ãªã¢ãã€ã©ããªãã€ãæªåœ±é¿ãåããªããã
ã«æ³šæããªããã°ãªããªãã æ¬çºæã¯ãå°ãªããšãäžæ¹ã®æåãæ°Žæ§ççåŠ
ç液äœã«ãã溶ãã«ãããããããã®çæ°Žæ§åã¯
芪氎æ§ã«ãããŠçžäºã«èããç°ãªãå°ãªããšãïŒ
çš®ã®æŽ»æ§æåãå«ãå»è¬è£œå€ã«é¢ããããã®ãã
ãªçµæç©ã«ãããŠã掻æ§æåã¯äžè¬ã«ãççåŠç
液äœãžã®æº¶è§£ãä¿é²ããããã«ãæ倧ã®è¡šé¢ç©ã
çãã極ããŠåŸ®çŽ°ãªåœ¢ã§å©çšãããªããã°ãªããª
ããããããªãããäžæ¹ã®æåãçæ°Žæ§ãæãã
å Žåã«ã¯ããã®æåã®åŸ®çŽ°ãªç²åã¯ç¬¬äºã®ãçžå¯Ÿ
çã«èŠªæ°Žæ§ã®æåã®çŽ°åãããç²åã®è¡šé¢ã被èŠ
ããåŸã€ãŠåŸè ã®æåãäœæ¶²ã«æº¶è§£ããèœåãè
ããæå¶ããåŸåããããããã äºå®ãçžå¯Ÿçã«çæ°Žæ§ã®æåãçžå¯Ÿçã«èŠªæ°Žæ§
ã®æåããçžå¯Ÿçã«å€ãééã§äœ¿çšããªããã°ãª
ããªãå Žåãæã ãããåŸã€ãŠçµ±èšçã«ã¯èŠªæ°Žæ§
ã®ç²åããç¹ã«é å€åã¯ã«ãã»ã«å€ã®åœ¢ã§åã ã®
æäžå€ã補é ãããã䜿çšãããæé åã¯é ç²æ
äœã®éã«åœ¢æãããäžçš®ã®å°ããåéç²åã®ç¶æ
ã§ãå€æ°ã®åŸ®çŽ°ãªçæ°Žæ§ç²åã§è¢«èŠãããåŸåã
極ããŠé¡èã§ããããã®çµæã芪氎æ§ç©è³ªã®ãã€
ãªã¢ãã€ã©ããªãã€ã¯æªåœ±é¿ãåããäœäžãã補
å€ã¯æ£è ã®çŸå®ã«åããæè¬éã®æå³ã§äžå®å®ãª
æåã瀺ãããšã«ãªãããã®ããšã¯ãéçã®ç æ°
ã®æ²»çã«ãããŠé倧ãªå°é£ãèµ·ããããšãããã
ãŸãããã®ãããªçµæç©äžã®çæ°Žæ§ç©è³ªèªäœãäž
å®å®ãªãã€ãªã¢ãã€ã©ããªãã€ãã瀺ããªãããš
ãæã ããã ãããã«ããŠãããã®ãããªçµæç©ã«ãããŠè¬
åŠçç®çã¯ãåºæ¥ãã ãäœãæäžéã§ã奜ãŸãã
ã¯å€æ°ã®é å€åã¯ã«ãã»ã«ã§ã¯ãªããïŒåã®é å€
åã¯ã«ãã»ã«ã§ãåæåãæé«ã®ãã€ãªã¢ãã€ã©
ããªãã€ã瀺ãããã«ããããšã§ãããæŽã«ãæ
åã®ãã€ãªã¢ãã€ã©ããªãã€æ°ŽæºãæãŸããã¯äž
æ§ã§ãããå³ã¡å€æ°ã®æ£è ã®åå¿ãçµ±èšçã«åæ
ããæã«æ¯èŒçã«äœãå€åä¿æ°ã瀺ãããã«ã補
å€ãã¹ãã§ããã ãããã®åé¡ã説æããæ¬çºæã®äžå®æœæ æ§ã
瀺ãé©äŸã¯ããããã¯ãããã¢ãžãåã³ããªã¢ã
ãã¬ã³ã®éå§è€åè¬ã§ããã ãããã¯ãããã¢ãžãã¯ãå©å°¿åã³éå§ã®ãã
æè¬ããæ²»çããããã«æ£è ã«æäžããå ¬ç¥åå³
è¬ã§ãããé«è¡å§ã«å¯ŸããŠæçãªäœçšãçãããš
å ±ã«ãå©å°¿äœçšãè èãå¿èåã¯èèã®æ©èœäžå š
åã¯ãã®ä»ã®åå ã§èµ·ããæµ®è «ãæ²»çããã®ã«åœ¹
ç«ã€ã ããããªããããããã¯ãããã¢ãžããåå³ã§
æäžããå Žåã«èµ·ããåé¡ã®äžã€ã¯ããã®æè¬ã«
ããæ£è ã®ã«ãªãŠã æ倱ãèµ·ãããããããã®æ
倱ãéå°ã§ãããããã«ãã€ãŠäžææãªäœã«ãªãŠ
ã è¡çç¶ãèµ·ããããšããããæ£è ã«ãããäœã«
ãªãŠã è¡çã®äžææãªçµæãšããŠã¯ãçèèçž®ã
äžè¬çç²åŽåã³æ£è ã«çŸãã«ãããçš®ã ã®è¬å€ã«
察ããå¿èã®é倧åå¿ããããã«ãªãŠã äŸçµŠå€ã
åŠæ¹ãããããããã«ããæŽã«äžå©ãªå¯äœçšãäŸ
ãã°ã朰çåã³ç©¿åçãèµ·ããåŸãåæã圢æã
ãèè žç®¡å·å®³ãèµ·ããããšãããã ããªã¢ã ãã¬ã³ã®æäžãšçµã¿åãããŠãããã¯
ãããã¢ãžããæäžããããšãæ¢ã«ç¥ãããŠã
ããããªã¢ã ãã¬ã³ã¯æ£è ã®èº«äœããã®ã«ãªãŠã
ã®æŸåºãé 延ãããããšã«ãã€ãŠäœã«ãªãŠã è¡ç
ãæå¶ããèœåãæããããã®ãããªåŸæ¥ã®ç 究
ã«ã€ããŠã¯ãç±³åœç¹èš±ç¬¬3081230å·æ现æžãã³ãŒ
ãã«ïŒKohvakkaïŒçèãã¡ã€ã³ããã³ã¹ã»ãª
ãã»ã«ãªãŠã ã»ãã©ã³ã¹ã»ããŠã¢ãªã³ã°ã»ãã€ãŠ
ãŒã¬ãã€ãã¯ã»ã»ã©ãã€ïŒMaintenance of
Potassium Balance During Diuretic
TherapyïŒãã205Acta Med.Scand.205å·»ã319ã
324é ïŒ1979ïŒåã³ã¿ã³ãã³ããŠã
ïŒTannenbaumïŒçèããžã»ã€ã³ãã«ãšã³ã¹ã»ãª
ãã»ããŒã»ãžã»ããªãŒã ã»ãªã³ã»ãžã»ã¢ã¯ãã€ã
ã€ãã€ã»ãªãã»ã¢ã»ãã€ãŠãŒã¬ãã€ãã¯ã»ãšã€ãž
ãšã³ãïŒThe Influence of Dosage Ferm on
the Activity of ïœ Diuretic AgentïŒã ã¯ãª
ãã«ã«ã»ãã¢ãŒãã³ããžã€ã»ã¢ã³ãã»ã»ã©ããŠãŒ
ãã€ã¯ã¹ïŒClinical Pharmacology and
TherapeuticsïŒãïŒå·»No.ïŒã598ã604é ïŒ1968ïŒ
ã«èšèŒãããŠãããäžè¬ã«ãã®ãããªåŸæ¥ã®äžå
é補å€ã¯ãçš®ã ã®çŽ°åãããæåããã¹ãŠäžç·ã«
åå¯ã«æ··åããããšã«ãã€ãŠè£œé ãããã ããããªãããåŸæ¥æäŸããããã®ãããªè€å
ç©ã«é¢ããŠæªã 解決ãããŠããªãåé¡ã®äžã€ã¯ã
è€åçµæç©ãæ£è ã«äžå®å®ã§äžå®å šã«ããåžåã
ãããæåã®æ¯èŒçã«äœããã€ãªã¢ãã€ã©ããªã
ã€ããçããªãããšã§ããããã®ããšããæ£è ã«
å¿ èŠãªããªã¢ã ãã¬ã³ã®èŠæãã®éãäžæçã«ãª
ããåã¯å¢å ããã ãŸããå¥ã®åé¡ãšããŠããã€ãªã¢ãã€ã©ããªã
ã€ã®æé©ãªåå³ãããã¯ãããã¢ãžãã§æ²»çäžã®
æ£è ããã®åŸãããªã¢ã ãã¬ã³âãããã¯ããã
ã¢ãžãè€åç©æ²»çã«ç§»ããŠäœã«ãªãŠã è¡çãæå¶
ããè©Šã¿ãããå Žåã«ãé«è¡å§åã¯æµ®è «ã®æå¹ãª
æå¶ãæ倱ããå±éºããã€ãããããã¯ãããã¢
ãžãã®ä»¥åã«ã¯èš±å®¹ãããæå¹ã§ãã€ãæäžéã¯
ãã€ãªã¢ãã€ã©ããªãã€ã®äœäžã«ãã€ãŠçžå¯Ÿçã«
äžé©åœã«ãªããæŽã«ãäœã«ãªãŠã è¡çã®æå¹ãªæ
å¶åã¯å埩ãèªããããªãã€ãããã®ãããªå°é£
ã¯ãæžæ¿æ¶²ãåã¯åå¥ã®é å€è¥ããã¯ã«ãã»ã«äž
ã®æŽ»æ§æåã®åå¥ã®åºäœæäžéãæäžããããšã«
ãã€ãŠå æããããšèãããããããããªããã
ãã®ãããªã¢ãããŒãã¯äžè¬ã«ãæ®ã«ãé©åã«åŠ
æ¹ãããæè¬éãåžžã«æåããããšã«æ£è ã®æ¿è«Ÿ
ãèŠããã®ã§ãæãŸãããªãã åŸã€ãŠããããã¯ãããã¢ãžãåã³ããªã¢ã ã
ã¬ã³ã®æ§è³ªåã³å»åŠçå©ç¹ã䞊ã³ã«äž¡è ãçµã¿å
ãããŠæäžããããšããçããäºæž¬ãããå©ç¹ã¯
é·ãç¥ãããŠããããåæåãæé©ãªãã€ãªã¢ã
ã€ã©ããªãã€ã瀺ããé«ãå®å šæ§åã³è¬åŠçå¹æ
ãæããããã«ããããã®ïŒçš®ã®ç©è³ªãé åãã
å»è¬çµæç©ãæ±ããããŠãããç¹ã«ããããã¯ã
ããã¢ãžãåã³ããªã¢ã ãã¬ã³ãå«ã¿ãå©å°¿äœçš
åã³éå§äœçšã䜵æããåç¬æäžã®ãããã¯ãã
ãã¢ãžãåã³ïŒåã¯ããªã¢ã ãã¬ã³ã®ãã€ãªã¢ã
ã€ã©ããªãã€ã«å°ãªããšãã»ãŒå¹æµããã掻æ§æ
åã®ãã€ãªã¢ãã€ã©ããªãã€ã瀺ããæå°çžå¯Ÿé
ã®ããªã¢ã ãã¬ã³ã䜿çšããŠãããã¯ãããã¢ãž
ãèªçºäœã«ãªãŠã è¡çãæå¶åã¯å埩ããäžåé
åºäœæäžçµæç©ãæ±ããããŠããã çºæã®æŠèŠ æ¬çºæã¯ãçŸåšå¥œãŸããæ æ§ã§ããããã¯ãã
ãã¢ãžãåã³ããªã¢ã ãã¬ã³ã®äž¡æ¹ãå«ã¿ãç¹ã«
åºäœã®å€åœ¢ã§ãããæé©ã®ãã€ãªã¢ãã€ã©ããªã
ã€ã®ç¹æ§åã³æ§è³ªãæããäž¡æåã®ããåäžãªåž
åæ§ãæããæå°çšéã®ããªã¢ã ãã¬ã³ã§äœã«ãª
ãŠã è¡çãæå¶åã¯å埩ããªããæé©ãªå©å°¿åã³
éå§æŽ»æ§ãçºæ®ãããå»è¬çµæç©ãæäŸãããã®
ã§ããã åŸã€ãŠãæ¬çºæã®ç®çã¯ããããã¯ãããã¢ãž
ãåã³ããªã¢ã ãã¬ã³ãçµã¿åãããŠå«ã¿ãäžæ
æãªäœã«ãªãŠã è¡å¯äœçšãæå¶åã¯å埩ããªãã
éå§âå©å°¿å€ãšããŠäœ¿çšããã®ã«é©åãããå®å š
ãã€æå¹ãªå»è¬çµæç©ãæäŸããããšã«ããã æ¬çºæã¯ãæŽã«ãå°ãªããšãïŒçš®ã®æŽ»æ§æåã
å«ã¿ãå°ãªããšãäžæ¹ã®æåãççåŠç液äœã«ã
ã溶ãã«ãããèããç°ãªãçæ°Žæ§åã³ïŒåã¯èŠª
æ°Žæ§ãæããè¬å€ã®ãã€ãªã¢ãã€ã©ããªãã€ãå
äžããççåŠçåžåæåã®äžæ§æ§ãå¢å ããŠãã
å»è¬çµæç©ã®è£œé æ¹æ³åã³çæããçµæç©ãæäŸ
ããããšãç®çãšããã æ¬çºæã®æŽã«ç¹æ®ãªç®çã¯ããããã¯ãããã¢
ãžãåã³ããªã¢ã ãã¬ã³ãå«ã¿ããã®çµæç©ã®æŽ»
æ§æåãåäžã«åžåãããåå³ãããã¯ãããã¢
ãžãåã¯åå³ããªã¢ã ãã¬ã³æäžã«ãã€ãŠçãã
ãã®ã«å¹æµããé«ããã€ãªã¢ãã€ã©ããªãã€ãç
ããå»è¬çµæç©ã®è£œé æ¹æ³ãçæããå»è¬ããã³
ãã®äœ¿çšæ¹æ³ãæäŸããããšã«ããã æ¬çºæã®æŽã«å¥ã®ç®çã¯ãé åããæå°éã®ã
ãªã¢ã ãã¬ã³ã䜿çšããªãããããã¯ãããã¢ãž
ãèªçºäœã«ãªãŠã è¡çãæå¶åã¯å埩ããããšã®
ã§ããçµæç©åã³é¢é£ããæ¹æ³ãæäŸããããšã«
ããã äžè¬ã«ãæ¬çºæã®ç¬¬äžã®ç¹å¥ãªç®çã¯ãæå°é
ã®ããªã¢ã ãã¬ã³ã䜿çšããæå¹ãªãã€ãªã¢ãã€
ã©ããªãã€ãçãããããã¯ãããã¢ãžãèªçºäœ
ã«ãªãŠã è¡çãåé¿åã¯æå¶åã¯å埩ããçµç©ã
æäŸããããšã§ãããäžè¬ã«ãäœã«ãªãŠã è¡çã¯
çŽ3.5mEgïŒïŒ¬ä»¥äžã®è¡æž ã«ãªãŠã æ¿åºŠã§ååšã
ããšèããããã æ¬çºæã®ãããã®åã³ä»ã®ç®çãäžèšã®è©³çŽ°ãª
説æããæããã«ããã æå©ãªæ æ§ã®èª¬æ æ¬çºæã®å¥œãŸããå®æœæ æ§ã«ãããŠã¯ãããã
ã¯ãããã¢ãžãïŒïŒâã¯ããâïŒïŒïŒâãžããã
â2HâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãžã³âïŒâ
ã¹ã«ãã³ã¢ããâïŒïŒïŒâãžãªãã·ãïŒãããªã¢
ã ãã¬ã³ïŒïŒïŒïŒïŒïŒâããªã¢ããâïŒâããšã
ã«ãããªãžã³ïŒãåã³è¬åŠçã«èš±å®¹ãããç¡æ¯æ§
æ æç©è³ªåã¯ææã®è¬çäœçšãçããä»ã®ç©è³ªãš
çµã¿åãããã æ¬çºæã®å»è¬çµæç©ã®è£œé æ¹æ³ã®å¥œãŸããå®æœ
æ æ§ã¯ãããªã¢ã ãã¬ã³åã³ãããã¯ãããã¢ãž
ãããããªã¢ã ãã¬ã³ïŒãããã¯ãããã¢ãžãã®
çŽ1.75ã1.25ïŒïŒã®ééæ¯ã§æºåããå·¥çšãå«
ãããããã®æåãå¥ã ã«ããããã®ãã€ãªã¢ã
ã€ã©ããªãã€ã®åäžã«å¯äžããä»å çæ æç©è³ªãš
æ··åãããããããã®æ··åç©ãé ç²ããåŸã«ãçµ
ã¿åãããæ··åãããçããå»è¬çµæç©ã¯åºäœã®
å€åœ¢ã§ãç¹ã«é å€åã¯ã«ãã»ã«ãšããŠæäŸããã®
ã奜ãŸããã ããªã¢ã ãã¬ã³ã®éã¯ãééåºæºã§ããããã¯
ãããã¢ãžãã®éã®çŽ1.75ã1.25åã®ç¯å²ã§ãã
ããçŽ1.5ïŒïŒã§ããã®ããæå©ãã€æã奜ãŸã
ããçšèªãããªã¢ã ãã¬ã³ééåºæºãã¯ã以äžã«
ãããŠãããªã¢ã ãã¬ã³ã®éã«å¯Ÿããå¥ã®æåã®
éïŒééåºæºïŒã®æ¯ãè¡šããã®ãšããã ããªã¢ã ãã¬ã³æåèªäœã¯åŸ®çŽ°ã«ç²ç ããã圢
ã§ã奜ãŸããã¯å°ãªããšãçŽ95ïŒ ã200ã¡ãã·ãŠ
ã®ç¯©ãééããçšåºŠã§ããããããçŽ25ã75ïŒ
ïŒããªã¢ã ãã¬ã³ééåºæºã§ïŒã奜ãŸããã¯çŽ35ã
55ïŒ ã®ãŠã€ããã³ã°å€ãäŸãã°ç²æ«ã»ã«ããŒã¹ã
N.F.ãïŒC6H10O5ïŒoãå«ã第äžã®æ··åç©ã«ããã
ãšãã§ãããé©åœãªãŠã€ããã³ã°å€ã¯ã¡ã³ãã«ç€Ÿ
ïŒMendell Co.ïŒããåååãã¬ã¯ã»ã«
ïŒREXCELïŒããçŸåšã¯ãœã«ã«ãŒãããã¯
ïŒSOLKAâFLOKïŒBWâ100ãã§åžè²©ãããŠã
ããã®ãåã¯ã·ãã³ã»ã±ãã«ã«ç€Ÿ
ïŒSitcoChemicalïŒããåååããšã¯ã¹âã»ã«
ïŒEXâCELïŒãã§åžè²©ãããŠãããã®ã§ãããã
ã®ãããªãŠã€ããã³ã°å€ã¯ãæ°Žæ§ççåŠç液äœã«
觊ãããšãã«ãåŸã«åœ¢æãããé¡ç²ïŒä»¥äžåç §ïŒ
å ã«æ°ŽãåžåŒããŠèšæœ€ããé¡ç²ãç Žå£ããã®ã«æ
å¹ã§ããã¹ãã§ããããã®ç©è³ªã¯çµæç©äžã§åžã
äžãäœçšãé«ããããã«ãçŽ200ã¡ãã·ãŠã®ç¯©ã
ééãããã倧ãã瞊ã®å¯žæ³ãæããã®ãæå©ã§
ããã ãã®æ··åç©ã«æŽã«çŽ20ã240ïŒ ïŒããªã¢ã ãã¬
ã³ééåºæºïŒã奜ãŸããã¯çŽ150ã190ïŒ ã®çŽ°åã
ããçµåå€â厩å£å€ãäŸãã°åŸ®æ¶æ§ã»ã«ããŒã¹ã
N.F.ïŒC6H10O5ïŒoãæ·»å ãããé©åœãªçµåå€â厩
å£å€ã¯ãFMCã³ãŒãã¬ã€ã·ãšã³ããåååãã¢
ãã»ã«ïŒAVICELïŒPHâ102ãã§åžè²©ãããŠã
ããã®ã§ãããé©åœãªæ¹¿æœ€å€ãäŸãã°ã©ãŠãªã«ç¡«
é žãããªãŠã ãããã·ã«ç¡«é žãããªãŠã CH3
ïŒCH2ïŒ10CH2OSO3Naããããªã¢ã ãã¬ã³ééåº
æºã§çŽïŒã10ïŒ ã奜ãŸããã¯çŽïŒãïŒïŒ ã®éã§æ·»
å ããããšãã§ãããé©åœãªç©è³ªã¯ãåååãã
ãããã€ãã¯ã¹ïŒMaprofixïŒãïŒãªããã¯ã¹ã»ã±
ãã«ã«ç€ŸïŒOnyx Chemical Co.ïŒãã®äžã«åžè²©ã
ããŠããã ä»ã®è¬åŠçã«èš±å®¹ããããäžæŽ»æ§ãªç¡æ¯æ§æ æ
ç©è³ªãæŽã«ååšããŠãããããããã®æåããã¹
ãŠäžç·ã«æ··åããŠç¬¬äžã®æ··åç©ã補é ãããè¬åŠ
çã«äžæŽ»æ§ãªç©è³ªãšããŠãã®ãããªç¬¬äžæ··åç©äž
ã«å«ãã§ããŠããä»å çæåã¯ããã¹ãŠçŽ°åãã
ã圢ã§ããªã¢ã ãã¬ã³ééåºæºã§çŽïŒã22ïŒ ã奜
ãŸããã¯çŽ10ã18ïŒ ã®éã®åŽ©å£å€ãäŸãã°ã¯ãã¹
ã«ã«ã¡ãâã¹ãããªãŠã ãN.F.ïŒäº€åçµåããã
ããªãŠã ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ç©è³ªïŒã§ã
ã€ãŠãããé©åœãªç©è³ªã¯åååãAcâDiâSolã
ïŒFMCã³ãŒãã¬ã€ã·ãšã³ïŒåã³ãCLDããããã±
ã€ã»ã»ã«ããŒã¹ç€ŸïŒBukeye Cellulocse Corp.ïŒã
ã®äžã§åžè²©ãããŠãããã®ã§ããã ãã®ç¬¬äžæ··åç©ã«ééåºæºã§çŽïŒã12ïŒ ã奜ãŸ
ããã¯çŽïŒã10ïŒ ã®éã®è£œå€æ»æ²¢å€ãäŸãã°ã¹ã
ã¢ãªã³é žãã°ãã·ãŠã ãšã©ãŠãªã«ç¡«é žãããªãŠã
ã®æ··åç©ïŒåè ã®94éééšåã³åŸè ã®ïŒéééšã
æºåãã奜ãŸããã¯æå湿åŒæ··åãã次ã«ä¹Ÿç¥
ããããªã³ã°ããŠè£œé ïŒãæ·»å ãããããã®æ··å
ç©ã¯ãäŸãã°ã¹ãã¢ãªã³é žãã°ãã·ãŠã ãN.F.
ïŒãªã¯ã¿ãã«ã³é žãã°ãã·ãŠã å¡©Mg
ïŒC18H35O2ïŒ2ïŒ94éšåã³ã©ãŠãªã«ç¡«é žãããªãŠã
N.F.ïŒããã·ã«ç¡«é žãããªãŠã CH3
ïŒCH2ïŒ10CH2OSO3NaïŒïŒéšããæããããã®çš®
ã®é©åœãªæ»æ²¢å€ã¯ãåååãStearâïŒâWet
ïŒãã®äžã«åžè²©ãããŠãããã®ã§ãããæŽã«ãé©
åœãªæµåæ§åäžå€ãäŸãã°ã³ãã€ãç¶äºé žåçªçŽ
ãããªã¢ã ãã¬ã³ééåºæºã§çŽïŒãïŒïŒ ã奜ãŸã
ãã¯çŽ2.5ãïŒïŒ ã®éã§å ããããšãã§ãããé©
åœãªç©è³ªã¯åååãCabâïŒâSilãããã€ãã
ãã»ã³ãŒãã¬ã€ã·ãšã³ïŒCabot CorporationïŒå
ã³ãã¢ãšã·ã«ïŒAerosilïŒãïŒãã°ããµç€Ÿ
ïŒDegussaïŒInc.ïŒãã®äžã«åžè²©ãããŠãããã®ã§
ããã 以äžã«ãããŠãçšèªããããã¯ãããã¢ãžãé
éåºæºãã¯ãããã¯ãããã¢ãžãã®éã«å¯Ÿããå¥
ã®æåã®ãééåºæºã§ã®éã®æ¯ã瀺ãã 现åããããããã¯ãããã¢ãžãã奜ãŸããã¯
å°ãªããšã95ïŒ ã100ã¡ãã·ãŠã®ç¯©ãééããã
ããã¯ãããã¢ãžããçŽ120ã240ïŒ ïŒãããã¯ã
ããã¢ãžãééåºæºã§ïŒã奜ãŸããã¯çŽ160ã200
ïŒ ã®é©åœãªçµåå€â厩å£å€ãäŸãã°åŸ®æ¶æ§ã»ã«ã
ãŒã¹ãN.F.ïŒåèšïŒãåã³ãããã¯ãããã¢ãžã
ééåºæºã§çŽïŒã16ïŒ ã奜ãŸããã¯çŽ10ã12ïŒ ã®
厩å£å€ãäŸãã°ã¯ãã¹ã«ã«ã¡ããŒã¹ãããªãŠã ã
N.F.ïŒåèšïŒãåã³ãããã¯ãããã¢ãžãééåº
æºã§çŽ0.5ãïŒïŒ ã奜ãŸããã¯çŽïŒãïŒïŒ ã®æµå
æ§åäžå€ãäŸãã°ã³ãã€ãç¶äºé žåçªçŽ ãN.F.
ïŒSiO2ïŒãåã³ãããã¯ãããã¢ãžãééåºæºã§
çŽ0.5ãïŒïŒ ã奜ãŸããã¯çŽïŒãïŒïŒ ã®éã®æ»æ²¢
å€ãäŸãã°ã¹ãã¢ãªã³é žãããªãŠã ïŒã©ãŠãªã«ç¡«
é žãããªãŠã ïŒ94ïŒïŒïŒãæ··åããããšã«ãã€ãŠ
第äºã®æ··åç©ãäœããé©åœãªæµåæ§åäžå€ã¯åå
åãCabâïŒâSilãïŒãã€ãããã»ã³ãŒãã¬ã€ã·
ãšã³ïŒåã³ãã¢ãšãã·ã«ãïŒãã°ããµïŒã®äžã§åž
販ãããŠãããã®ã§ããã ããããã®æŽ»æ§æååã³æ æç©è³ªããæããå¥
å¥ã«è£œé ããïŒçš®ã®æ··åç©ã®ããããããå åã«
æ··åããå¿ èŠã«å¿ããŠãæçšãªè¬åŠççšéã«æé©
ãªç²åŸã«æŽã«ããªã³ã°ããã ãããã®ïŒçš®ã®æ··åç©ã次ã«ããããå¥ã ã«ã
åæ··åç©ã®é¡ç²ã補é ããããã«å§çž®ããããã®
åå¥ã®å§çž®å·¥çšã«ããåæ··åç©ã®å§çž®ç©è³ªè€åç©
ããäŸãã°åã ã®æŽ»æ§æåç²åãåèšã®æ·»å ç©ç²
åãšã®ãå®è³ªçã«åäžãªåå¯ãªç©ççæ··åç©ãšã
ãŠååšããããã«å€§ãããã€ã¹ã¯åã¯ã·ãŒãã®åœ¢
ã§åœ¢æããã 次ã«ãå§çž®ç©è³ªãå¥ã ã«çŽç æäœã«ä»ããŠç²åœ¢
ã«åå²ããåæ··åç©ã®ããããã®é¡ç²ãå掻æ§æ
ååã³åèšã®çš®ã ã®æ·»å å€ããæãããã«ããã
å§çž®ç©ããããããŠåœ¢æããé¡ç²ã¯é©åãªæ§é ç
äžäœæ§ãæããäžèšã®æäœã§ç¹å®ã®ç©äœãšããŠå
åšãã¹ãã§ããã æ¬çºæã®å¥œãŸããå®æœæ æ§ã§ãïŒçš®ã®ãããã
ã®æ··åç©ãå¥ã ã«åŠçããéã«ãæ··åç©ããã€ã
ããã«ïŒFitzmillïŒãNo.00篩ã«éãã®ã奜ãŸããã
æ··åç©ãå¥ã ã«å§çž®ããåŸãæ··åç©ãçŽç ããŠ
åã ã®æ··åç©ã®ããããé¡ç²ã圢æããé ç²ãã
ç©è³ªãã«ãã»ã«ã«ã¯ãã€ãããã«No.ïŒç¯©ãé å€ã«
ã¯ãã€ãããã«No.2Aã«éãããããã®ç®çã§ã
å¿è«ãåçãªæ©èœã®ä»ã®è£ 眮ã䜿çšããããšãã§
ããã ããããŠåœ¢æããé¡ç²ã¯ãïŒmmãã倧ãããã®
ãïŒïŒ 以äžã§ããã0.075mmããå°ãããã®ã20
ïŒ ä»¥äžã§ãããç¹ã«ã«ãã»ã«å€ãäœãã¹ãå Žåã«
ã¯ã1.5mmãè¶ãããã®ãïŒïŒ 以äžã§ããç²åŸç¯
å²ãæããã¹ãã§ããã ãã®åŸã第äžåã³ç¬¬äºã®ããããŠåœ¢æããé¡ç²
ãäžç·ã«æ··åããŠç¬¬äžã®è€åæ··åç©ã«ãããæ¬çº
æã®å¥œãŸããå®æœæ æ§ã§ã¯ã第äžã®æ··åç©ã«æŽã«
æ»æ²¢å€ãäŸãã°ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠ
ãªã«ç¡«é žãããªãŠã ïŒäŸãã°94ïŒïŒééæ¯ïŒã®æ··
åç©ïŒå¥œãŸããã¯æ¹¿åŒæ··åãã也ç¥ããããªã³ã°
ããïŒãæ··åãããæ»æ²¢å€ã¯ïŒçš®ã®æ··åç©ã®åèš
æ··åééã®çŽ0.2ã1.0ïŒ ã奜ãŸããã¯çŽ0.4ã0.7
ïŒ ã§ãã€ãŠãããè€åçµæç©ãæçµçã«ã«ãã»ã«
å€ã«ããå Žåãé©åœãªå®å®å€ãè¡šé¢æŽ»æ§å€åã³æ
èå€ãååšããŠããããé å€ãäœãå Žåã«ã¯ãç
è²å€ãäŸãã°ïŒ€ïŒïŒ£ã€ãšããŒïŒyellowïŒïŒ10ã¢
ã«ãããŠã ã¬ãŒããå¿ èŠã«å¿ããŠé©åœãªçè²éã§
æ·»å ããããšãã§ããã åèšæ¹æ³ã§è£œé ãããé ç²ããæ··åããè€åçµ
æç©ãäžåé補å€ãäŸãã°é å€åã¯ã«ãã»ã«å€ã«
ããããšãã§ããã æ¬çºæã®å¥œãŸããå®æœæ æ§ã§ã¯ãè€åæ··åç©ã®
æçµçäžåé補å€ã¯ããããã¯ãããã¢ãžããçŽ
25mgã100mgã®éã§å«ãã§ããŠãããæãŸããã¯
掻æ§å»è¬æåãå³ã¡ããããã¯ããããžãåã³ã
ãªã¢ã ãã¬ã³ã®åèšééãçŽ62.5mgã25mgã«ãªã
çšåºŠã§å«ãã§ããŠãããäŸãã°1.5ïŒïŒã®ééæ¯
ã§ã¯ãããªã¢ã ãã¬ã³ïŒãããã¯ãããã¢ãžãã®
äžåéåã¯37.5ïŒ25mgã75ïŒ50mgåã¯150ïŒ100mg
ã§ãã€ãŠããã極ããŠæå¹ãªééæ¯ã¯75ïŒ50ã§ã
ãããšãå€ã€ããäžè¬ã«ãäžæ¥åœããã®ããªã¢ã
ãã¬ã³ã®æ£è ã®ç·æ¶è²»éãçŽ150mg以äžã«ãäžæ¥
åœããã®ãããã¯ãããã¢ãžãã®ç·æ¶è²»éãçŽ
100mg以äžã«éå®ããã®ãæãŸãããïŒæ¬æ现æžã«
ãããŠçšèªãæ£è ãã¯äººéãå«ããŠåç©çã®æå¡
ãè¡šãããã®ãšããïŒã é«ããã€ãªã¢ãã€ã©ããªãã€ã«å¯äžããæ¬çºæ
ã®äž»ãªç¹åŸŽã®äžã€ã¯ããã®è€åçµæç©ã®çæãã
ïŒåé補å€ãççåŠç液äœã®ååšã§äºã圢æãã
åã ã®é¡ç²ã«è¿ éã«åŽ©å£ãããèœååã³ãã®åŸã«
ããããã®é¡ç²ããã®æ¶²äœäžã§æŽã«å°ããç²ç¶æ
åã«ç Žå£ããèœåã«é¢ããããã®ããšã¯ãçžå¯Ÿç
ç²åŸã®ç¹å®ã®èª¿ç¯ãçæ°Žæ§ç©è³ªåã³èŠªæ°Žæ§ç©è³ªã
å¥ã ã«é ç²ããåŸã«åããŠæ··åããããšãåã³ã
奜ãŸããå®æœæ æ§ã§ãç¹ã«çæ°Žæ§æåãšãšãã«ã
ãŠã€ããã³ã°å€ã䜿çšããããšã«ãã€ãŠéæãã
ãã ïŒã€ã®äŸå€ã¯ããããäžè¬ã«ãæ¬çºæã®å¥œãŸã
ãå®æœæ æ§ã§ã¯ã第äžåã³ç¬¬äºæ··åç©ã«é åãã
åºçºåæã®ã»ãšãã©ããçŽ95ïŒ ã200ã¡ãã·ãŠç¯©
ãééããç²åŸãæãããæå¹ãªåžãäžãäœçšã
æäŸããïŒæ°Žåãäžåé補å€å éšã«æµžéãããïŒ
ããã«ã¯ããŠã€ããã³ã°å€ã¯200ã¡ãã·ãŠã®ç¯©ã
ééãããã倧ãã瞊æ¹åã®å¯žæ³ãæããã§ãã§
ãããïŒçžå¯Ÿçã«èŠªæ°Žæ§ã®ïŒãããã¯ãããã¢ãž
ãç²åã¯ã95ïŒ ã200ã¡ãã·ãŠã®ç¯©ãééãã¹ã
ã§ããããçŽ95ïŒ ã100ã¡ãã·ãŠã®ç¯©ãééãã
ãã®ã§ãã€ãŠããããå¥ã ã«è£œé ãããæ··åç©äž
ã®æååã³æ æç©è³ªã®ç²åŸã¯ããã®åŸã«åœ¢æãã
ãé¡ç²ã®ç²åŸããå°ãªããšãïŒæ¡ä»¥äžå®è³ªçã«å°
ãããã¹ãã§ããã 掻æ§æåã®ãã¡ããããã¯ãããã¢ãžãã¯çžå¯Ÿ
çã«èŠªæ°Žæ§ã§ãããããªã¢ã ãã¬ã³ã¯çžå¯Ÿçã«ç
æ°Žæ§ã§ãããåèšã®ããã«ãåŸæ¥ã®ç©è³ªåã³çµæ
ç©ãçšããå Žåã«èµ·ããåé¡ã®äžã€ã¯ãåºäœè£œå€
ïŒåã³åéç©ïŒã®è¡šé¢ã«ããªã¢ã ãã¬ã³ã®åŸ®çŽ°ãª
ç²åããããåäžã«ååšããããã«ããæ°Žåã®æµž
éã«å¯Ÿããçæ°Žæ§éå£ãäœãããšã§ãã€ããšèã
ãããã®çŸè±¡ã®èµ·ããåå ã¯ãæããã«ãïŒçš®ã®
掻æ§æååã³ä»ã®åžžçšã®æé åã¯ã«ãã»ã«åœ¢ææ·»
å ç©ããã¹ãŠçŽ°åããã圢ã§ãäºãå¥åã®çµæç©
ãé¡ç²ã«ããããšãªããäžç·ã«æ··åããããšã§ã
ããããããŠæ°Žåã¯ãããã¯ãããã¢ãžããšæ¥è§Š
ããªãããåã¯æ¥è§Šãæå¶ããããåŸã€ãŠã補å€
ã¯è¿ éã«åŽ©å£ããããã®çµæããã®ãããªçµæç©
ã¯éããããäžå®å®ãªãã€ãªã¢ãã€ã©ããªãã€ã
瀺ãããšã«ãªãã ããã«åããŠãæ¬çºæã«ããã°ã掻æ§æåãæ··
åããåã«ä»ã®ç©è³ªãšå ±ã«å¥ã ã«é ç²ããã®ã§ã
çæ°Žæ§ç²ç¶ç©è³ªåã³èŠªæ°Žæ§ç²ç¶ç©è³ªã¯çžäºã«åé¢
ããŠããŠãããã«ããåèšã®ãããªè¡šé¢äœçšã¯å
é¿ãããåºäœè£œå€ã®äºå圢æé¡ç²ãžã®åŽ©å£ãä¿é²
ããããã®é¡ç²èªäœãè¿ éã«åŽ©å£ããŠæŽ»æ§æåã®
埮现ãªç²åãåæ£ãããããšãã§ããããã®å¹æ
ã¯ãããããã®é¡ç²ãç²ç ããŠç²åã®é²åè¡šé¢ç©
ãå¢å ããïŒããã«ãã溶解é床ãå¢å ããïŒã
ãšã«ãã€ãŠæŽã«åäžããã 以äžã«ç€ºãããã«ãããªã¢ã ãã¬ã³æåã®æº¶è§£
æ§åã³ãã€ãªã¢ãã€ã©ããªãã€ããæ¬çºæã®é¡ç²
ã®åœ¢ã§ååšããå Žåã«åäžããã æ¬çºææ¹æ³ã¯ãèªäœçžäºã«æ¬è³ªçã«åäžãªãã
ãããã®æåã®å¥ã ã®é¡ç²ã圢æããããæçµç
çµæç©ã«ãããŠã¯ãããšãªãé¡ç²ãäžç·ã«æ··åã
ããŠããç¹ã§äžåäžã§ãããæŽã«ãéçžæº¶æ§ã®å
é¡ãåé¿ããªããæçµç溶解æ§ãåäžããããã
ã«ãå¿ èŠã«å¿ããŠãçš®ã ã®æŽ»æ§æåãšå ±ã«ãç°ãª
ã補å€æ·»å ç©ã䜿çšããããšãã§ããã æ¬æ现æžã«ãããŠããç°çš®é¡ç²ããšã¯ãåã ã«
å¥åã®é¡ç²ãååšããäžæ¹ã®é¡ç²ãããªã¢ã ãã¬
ã³æåãå«ã¿ãä»æ¹ã®é¡ç²ããããã¯ãããã¢ãž
ããå«ãããšãæå³ãããåŸã€ãŠããã®çšèªã¯ã
å§ãã«ããªã¢ã ãã¬ã³åã³ãããã¯ãããã¢ãžã
ã®äž¡æ¹ãå«ãé¡ç²ã圢æããçµæç©ã«é¢ããŠã¯äž
é©åã§ãããçšèªãç°çš®é¡ç²ãã¯ãåãåã ã«è£œ
é ããé¡ç²ãæ··åããåŸãåã³äžç·ã«å§çž®ããã
åã¯å¡ç¶ã«ããŠæé ãã«ãã»ã«å€åœ¢æçã®ããã®
æ¯èŒç倧ããè€åé¡ç²ã圢æããå Žåã«ããæ¬çº
æã«ã¯é©åã§ããã ãã€ãªã¢ãã€ã©ããªãã€ãå¢å ãã第äºæ®µéã¯
äºã圢æããåã ã®é¡ç²ãççåŠçã«ãªãå°ãã
æåã«ç Žå£ããããšã§ããããŠã€ããã³ã°å€ã䜿
çšããããšã«ãã€ãŠãæ°Žåã¯é¡ç²ã®å éšã«åžåŒã
ããé¡ç²ãèšæœ€ããããŸãã厩å£å€åã³è¡šé¢æŽ»æ§
å€ããã®ãããªææã®ç Žå£ã«å¯äžããã æ¬çºæã®ãã®å®æœæ æ§ã®å©ç¹ã®äžã€ã¯ãããã
ãã®æŽ»æ§æåãç¬ç«ã«åèšã®å»è¬æ æç©è³ªãšæ··å
ããŠå¥ã ã®é¡ç²ãäœã€ãŠãç²åŸã®åŸ®çŽ°ãªæŽ»æ§æå
ãçµã¿åãããŠäœ¿çšããããšã«ãã€ãŠãé«ããã€
ãªã¢ãã€ã©ããªãã€ãéæã§ããçµæãšããŠãã
ãªã¢ã ãã¬ã³ã®äœçšã«ãããããã¯ãããã¢ãžã
èªçºäœã«ãªãŠã è¡çãæå¶åã¯å埩ãããããšã§
ãããçæ°Žæ§ãããã¯ãããã¢ãžãé¡ç²ã¯ããã®
ãããªé¡ç²ã®ç Žå£ãè£å©ãããããŠã€ããã³ã°å€
ãå«ãã§ããã®ã奜ãŸããã芪氎æ§ãããã¯ãã
ãã¢ãžãé¡ç²ã¯ãæ¬çºæã®é å€åã¯ã«ãã»ã«å€ã®
圢ã§ãã€ãŠããæ°Žåã¯ä»ã®äœæ¶²ã容æã«åžåãã
åºäœè£œå€ã®é©åãªç Žå£ãä¿é²ããŠé¡ç²ã«ãããé¡
ç²ã¯ã次ã«ã奜ãŸããã¯åŽ©å£å€ã湿最å€åã³ããª
ã¢ã ãã¬ã³é¡ç²äžã®ãŠã€ããã³ã°å€ã«ãã€ãŠå©æ
ãããŠåŽ©å£ããã å®æœäŸ äžèšã®å®æœäŸåã³ããŒã¿ã¯æ¬çºæã®æ¹æ³åã³çµ
æç©ãæŽã«èª¬æãããã®ã§ããã äŸ ïŒ ããªã¢ã ãã¬ã³ïŒãããã¯ãããã¢ãžãã®éé
æ¯ã1.5ïŒïŒã§ããæ¬çºæã®å»è¬çµæç©50Kgã補
é ãããããäžèšã®æäœã䜿çšããã ããªã¢ã ãã¬ã³ïŒç±³åœè¬å±æ¹ïŒçŽ9.38KgããŠã€
ããã³ã°å€4.75Kgãçµåå€â厩å£å€15.6Kgã厩å£
å€1.25Kgã湿最å€åã¯è¡šé¢æŽ»æ§å€ãäŸãã°ã©ãŠãª
ã«ç¡«é žãããªãŠã 500ïœãã¹ãã¢ãªã³é žãã°ãã·
ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒ750ïœ
åã³æµåæ§åäžå€250ïœãå«ã第äžæ··åç©ã補é
ããã 厩å£å€ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«
ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒåã³æµåæ§åäžå€æå
ãäºãå åæ··åããããã®äºåæ··åç©ã次ã«30ã¡
ãã·ãŠã®ç¯©ã«éããããªã¢ã ãã¬ã³ãçµåå€â厩
å£å€åã³ãŠã€ããã³ã°å€æåã篩ã§ç¯©éãããæ
åãå šéšã0.14m3ïŒ5ft3ïŒã®ïŒ¶åãã¬ã³ããŒã«å ¥
ããçŽ15åæ··åãããæ··åããç©è³ªã次ã«ãé«
éãè¡ææšé²ãã€ãããã«No.00ã¹ã¯ãªãŒã³ã«é
ããããããŠããªã³ã°ããæ··åç©ããã®åŸå¡ç¶ã«
ããããåã¯å§çž®ããŠç¬¬äžæ··åç©ã®é¡ç²ã«ããã
å¡ç¶ååã¯å§çž®ã«ããã1inåœããçŽïŒãïŒãã³
ã®å§åã䜿çšããŠãçŽåŸçŽ1.27cmïŒ1/2â³ïŒã®ç¡¬è³ª
ãã€ã¹ã¯åã¯åãçŽ0.32cmïŒ1/8â³ïŒã®ã·ãŒãçã
圢æããããã®å§çž®ããç©è³ªã次ã«äžé床ãã€ã
æšé²ãã€ãããã«No.2Aã¹ã¯ãªãŒã³ã«éããŠç²ç
ããé¡ç²ã圢æãããã«ãã»ã«å€ã補é ãããå Ž
åã«ã¯ã第äžæ··åç©ã®é¡ç²ã補é ãããã®æçµæ®µ
éã§ãã€ãããã«No.ïŒã¹ã¯ãªãŒã³ã代æ¿äœ¿çšããŠ
ãããã 现åããããããã¯ãããã¢ãžãïŒç±³åœè¬å±
æ¹ïŒçŽ6.25Kgãçµåå€â厩å£å€10.00Kgã厩å£å€
625ïœãæµåæ§åäžå€125ïœåã³ã¹ãã¢ãªã³é žãã°
ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒ
125ïœãïŒç·ã«æ··åããŠç¬¬äºæ··åç©ã補é ããã
é å€ã補é ããå Žåã«ã¯ãçè²å€çŽ125ïœãæ·»å
ããŠãããã厩å£å€ãã¹ãã¢ãªã³é žãã°ãã·ãŠ
ã ïŒã©ãŠãªã«ç¡«é žãããªãŠã åã³æµåæ§åäžå€
ïŒäœ¿çšããçè²å€ãäžç·ã«ïŒãäºãæ··åãããŸã
30ã¡ãã·ãŠã®ç¯©ã§ç¯©éããããããã¯ãããã¢ãž
ãåã³çµåå€â厩å£å€ãäºã18ã30ã¡ãã·ãŠã®ç¯©
ã§ç¯©éããŠå¡ãé€å»ããŠãããããã®åŸã«äœ¿çšã
ãæ··åãããªã³ã°ãé ç²æäœã¯ç¬¬äžæ··åç©ã«é¢ã
ãŠäœ¿çšããã®ãšåãã§ããã ããããŠåèšã®å¥ã ã®æ··åç©ã®äžŠè¡é ç²ã«ãã€
ãŠåå¥ã«è£œé ããç²ç ããæ··åç©é¡ç²ã次ã«å¥ã
ã«é·ããïŒmmïŒæ倧寞æ³ïŒãã倧ãããã®ãçŽïŒ
ïŒ ä»¥äžã§ãé·ãã0.075mmããå°ãããã®ãçŽ20
ïŒ ä»¥äžã§ããæŠç¥ã®ç²åŸç¯å²ã«ããªã³ã°ããã 次ã«ãééåºæºã§94ïŒïŒã®æ¯ã®æ··åããã¹ãã¢
ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã
250ïœã30ã¡ãã·ãŠã®ç¯©ã«éãããããã第äžå
ã³ç¬¬äºã®æ··åç©ããæã第äžåã³ç¬¬äºé¡ç²ã次ã«
æ··åããã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«
é žãããªãŠã ãšäžç·ã«0.14m3ïŒ5ft3ïŒã®ïŒ¶åãã¬
ã³ããŒäžã§çŽ15åæ··åããã é å€ã補é ãããå Žåã«ã¯ããã®æçµæ··åç©ã
次ã«åžžçšã®æé ãã¬ã¹ã§å§çž®ããããšãã§ããã ã«ãã»ã«åºäœè£œå€ã補é ããå Žåã«ã¯ãæ··åã
ãç©è³ªãé©åãªèªåè£ çœ®ã§åã«ãã»ã«äžã«å°å ¥ã
ãããšãã§ãããã«ãã»ã«å€ã補é ããå Žåãç
è²å€ãçãããšãã§ããç²åŸã®äžéã¯é·ãã1.5
mmãè¶ãããã®ãïŒïŒ 以äžã§ããçšåºŠã§ãã€ãŠã
ãã äžåé補å€ã¯ãåèšã®æ¹æ³ã§è£œé ãã0.4ïœã®
é å€ã§ããã®ãæãŸããããã®é å€ã¯ç¬¬äžæ··åç©
ããããªã¢ã ãã¬ã³ïŒç±³åœè¬å±æ¹ïŒçŽ75mgããŠã€
ããã³ã°å€38mgãçµåå€â厩å£å€125mgã厩å£å€
10mgã湿最å€åã¯è¡šé¢å€ãäŸãã°ã©ãŠãªã«ç¡«é žã
ããªãŠã ïŒç±³åœè¬å±æ¹ïŒïŒmgãã¹ãã¢ãªã³é žãã°
ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒïŒ
mgåã³æµåæ§åäžå€ïŒmgãå«ã¿ãæŽã«ç¬¬äºæ··åç©
ãããããã¯ãããã¢ãžãïŒç±³åœè¬å±æ¹ïŒ50mgã
çµåå€â厩å£å€80mgã厩å£å€ïŒmgãæµåæ§åäžå€
ïŒmgãã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«é ž
ãããªãŠã ïŒ94ïŒïŒïŒïŒmgåã³çè²å€ïŒmgãå«
ããæŽã«ãæçµçæ··åæäœã§æ·»å ããã®ã§ãã¹ã
ã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã
ïŒ94ïŒïŒïŒïŒmgãååšããã åèšã®æäœã«ãã補é ãããé å€äžã«ãããã¯
ãããã¢ãžã50mgåã³ããªã¢ã ãã¬ã³75mgãå«ã
奜ãŸããé å€ã¯ãäžèšã®ç©è³ªãäžèšã®éã§äœ¿çšã
ããã®ã§ããã
äœã«ãªãŠã è¡çãæå¶åã¯å埩ãããæ°èŠå»è¬çµ
æç©ã«é¢ãããæŽã«è©³è¿°ããã°ãæ¬çºæã¯ããã
ã¯ãããã¢ãžãïŒïŒâã¯ããâïŒïŒïŒâãžããã
â2HâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãžãâïŒâ
ã¹ã«ãã³ã¢ããâïŒïŒïŒâãžãªãã·ãïŒåã³ããª
ã¢ã ãã¬ã³ïŒïŒïŒïŒïŒïŒâããªã¢ããâïŒâããš
ãã«ãããªãžã³ïŒãå«ã¿ãäž¡æåã®åäžãããã€
ãªã¢ãã€ã©ããªãã€ã瀺ãæ°èŠå»è¬çµæç©ãæäŸ
ãããã®ã§ãããæŽã«ãäœã«ãªãŠã è¡å¯äœçšãé²
æ¢åã¯æé€ããªãããå©å°¿åã³éå§è€åè¬ã䜿çš
ããæäžããæ¹è¯ãããæ°èŠæ¹æ³ãæäŸãããæŽ
ã«ãæ¬çºæã¯çžå¯Ÿççæ°Žæ§åã³èŠªæ°Žæ§åã³ïŒåã¯
ççåŠç液äœãžã®æº¶è§£æ§ã«ãããŠçžäºã«èããç°
ãªãïŒçš®ä»¥äžã®æ²»æ§æåãå«ãå»è¬çµæç©ãäžè¬
çã«è£œé ããæ°èŠæ¹æ³ãæäŸãããã®ã§ããã åŸæ¥æè¡ æŽ»æ§æåãïŒçš®ä»¥äžå«ãå»è¬çµæç©ã補é ãã
ããšã¯å»åŠã«ãããŠäžè¬çã«èŠæ±ãããŠæ¥ããã
çŸåšãèŠæ±ãããŠããã屡ã ãæåãåã«æ··åã
ãŠå°é£ãªãå®å®æ§åã³ãã€ãªã¢ãã€ã©ããªãã€ã
ä¿æããããšãã§ãããä»ã®å Žåã«ã¯ããããã
ã®æŽ»æ§æåã¯ãçžäºã«åå¿ããåºäœè£œå€ã«ãããŠ
ããå®å®æ§ã®åé¡ãèµ·ããå¯èœæ§ãæããç¹æ®ã®
調補æ段ãå¿ èŠãšããããŸããä»ã®å Žåã«ã¯ãé
å€åã¯ã«ãã»ã«å€ã«ããå Žåã«çµæç©ã«å«ãŸãã
ã®ãæ®éã§ãããçš®ã ã®ãè¬åŠçã«èš±å®¹ãããäž
掻æ§æåã«ãã€ãŠãè€åå»è¬è£œå€äžã®æŽ»æ§æåã®
ãã€ãªã¢ãã€ã©ããªãã€ãæªåœ±é¿ãåããªããã
ã«æ³šæããªããã°ãªããªãã æ¬çºæã¯ãå°ãªããšãäžæ¹ã®æåãæ°Žæ§ççåŠ
ç液äœã«ãã溶ãã«ãããããããã®çæ°Žæ§åã¯
芪氎æ§ã«ãããŠçžäºã«èããç°ãªãå°ãªããšãïŒ
çš®ã®æŽ»æ§æåãå«ãå»è¬è£œå€ã«é¢ããããã®ãã
ãªçµæç©ã«ãããŠã掻æ§æåã¯äžè¬ã«ãççåŠç
液äœãžã®æº¶è§£ãä¿é²ããããã«ãæ倧ã®è¡šé¢ç©ã
çãã極ããŠåŸ®çŽ°ãªåœ¢ã§å©çšãããªããã°ãªããª
ããããããªãããäžæ¹ã®æåãçæ°Žæ§ãæãã
å Žåã«ã¯ããã®æåã®åŸ®çŽ°ãªç²åã¯ç¬¬äºã®ãçžå¯Ÿ
çã«èŠªæ°Žæ§ã®æåã®çŽ°åãããç²åã®è¡šé¢ã被èŠ
ããåŸã€ãŠåŸè ã®æåãäœæ¶²ã«æº¶è§£ããèœåãè
ããæå¶ããåŸåããããããã äºå®ãçžå¯Ÿçã«çæ°Žæ§ã®æåãçžå¯Ÿçã«èŠªæ°Žæ§
ã®æåããçžå¯Ÿçã«å€ãééã§äœ¿çšããªããã°ãª
ããªãå Žåãæã ãããåŸã€ãŠçµ±èšçã«ã¯èŠªæ°Žæ§
ã®ç²åããç¹ã«é å€åã¯ã«ãã»ã«å€ã®åœ¢ã§åã ã®
æäžå€ã補é ãããã䜿çšãããæé åã¯é ç²æ
äœã®éã«åœ¢æãããäžçš®ã®å°ããåéç²åã®ç¶æ
ã§ãå€æ°ã®åŸ®çŽ°ãªçæ°Žæ§ç²åã§è¢«èŠãããåŸåã
極ããŠé¡èã§ããããã®çµæã芪氎æ§ç©è³ªã®ãã€
ãªã¢ãã€ã©ããªãã€ã¯æªåœ±é¿ãåããäœäžãã補
å€ã¯æ£è ã®çŸå®ã«åããæè¬éã®æå³ã§äžå®å®ãª
æåã瀺ãããšã«ãªãããã®ããšã¯ãéçã®ç æ°
ã®æ²»çã«ãããŠé倧ãªå°é£ãèµ·ããããšãããã
ãŸãããã®ãããªçµæç©äžã®çæ°Žæ§ç©è³ªèªäœãäž
å®å®ãªãã€ãªã¢ãã€ã©ããªãã€ãã瀺ããªãããš
ãæã ããã ãããã«ããŠãããã®ãããªçµæç©ã«ãããŠè¬
åŠçç®çã¯ãåºæ¥ãã ãäœãæäžéã§ã奜ãŸãã
ã¯å€æ°ã®é å€åã¯ã«ãã»ã«ã§ã¯ãªããïŒåã®é å€
åã¯ã«ãã»ã«ã§ãåæåãæé«ã®ãã€ãªã¢ãã€ã©
ããªãã€ã瀺ãããã«ããããšã§ãããæŽã«ãæ
åã®ãã€ãªã¢ãã€ã©ããªãã€æ°ŽæºãæãŸããã¯äž
æ§ã§ãããå³ã¡å€æ°ã®æ£è ã®åå¿ãçµ±èšçã«åæ
ããæã«æ¯èŒçã«äœãå€åä¿æ°ã瀺ãããã«ã補
å€ãã¹ãã§ããã ãããã®åé¡ã説æããæ¬çºæã®äžå®æœæ æ§ã
瀺ãé©äŸã¯ããããã¯ãããã¢ãžãåã³ããªã¢ã
ãã¬ã³ã®éå§è€åè¬ã§ããã ãããã¯ãããã¢ãžãã¯ãå©å°¿åã³éå§ã®ãã
æè¬ããæ²»çããããã«æ£è ã«æäžããå ¬ç¥åå³
è¬ã§ãããé«è¡å§ã«å¯ŸããŠæçãªäœçšãçãããš
å ±ã«ãå©å°¿äœçšãè èãå¿èåã¯èèã®æ©èœäžå š
åã¯ãã®ä»ã®åå ã§èµ·ããæµ®è «ãæ²»çããã®ã«åœ¹
ç«ã€ã ããããªããããããã¯ãããã¢ãžããåå³ã§
æäžããå Žåã«èµ·ããåé¡ã®äžã€ã¯ããã®æè¬ã«
ããæ£è ã®ã«ãªãŠã æ倱ãèµ·ãããããããã®æ
倱ãéå°ã§ãããããã«ãã€ãŠäžææãªäœã«ãªãŠ
ã è¡çç¶ãèµ·ããããšããããæ£è ã«ãããäœã«
ãªãŠã è¡çã®äžææãªçµæãšããŠã¯ãçèèçž®ã
äžè¬çç²åŽåã³æ£è ã«çŸãã«ãããçš®ã ã®è¬å€ã«
察ããå¿èã®é倧åå¿ããããã«ãªãŠã äŸçµŠå€ã
åŠæ¹ãããããããã«ããæŽã«äžå©ãªå¯äœçšãäŸ
ãã°ã朰çåã³ç©¿åçãèµ·ããåŸãåæã圢æã
ãèè žç®¡å·å®³ãèµ·ããããšãããã ããªã¢ã ãã¬ã³ã®æäžãšçµã¿åãããŠãããã¯
ãããã¢ãžããæäžããããšãæ¢ã«ç¥ãããŠã
ããããªã¢ã ãã¬ã³ã¯æ£è ã®èº«äœããã®ã«ãªãŠã
ã®æŸåºãé 延ãããããšã«ãã€ãŠäœã«ãªãŠã è¡ç
ãæå¶ããèœåãæããããã®ãããªåŸæ¥ã®ç 究
ã«ã€ããŠã¯ãç±³åœç¹èš±ç¬¬3081230å·æ现æžãã³ãŒ
ãã«ïŒKohvakkaïŒçèãã¡ã€ã³ããã³ã¹ã»ãª
ãã»ã«ãªãŠã ã»ãã©ã³ã¹ã»ããŠã¢ãªã³ã°ã»ãã€ãŠ
ãŒã¬ãã€ãã¯ã»ã»ã©ãã€ïŒMaintenance of
Potassium Balance During Diuretic
TherapyïŒãã205Acta Med.Scand.205å·»ã319ã
324é ïŒ1979ïŒåã³ã¿ã³ãã³ããŠã
ïŒTannenbaumïŒçèããžã»ã€ã³ãã«ãšã³ã¹ã»ãª
ãã»ããŒã»ãžã»ããªãŒã ã»ãªã³ã»ãžã»ã¢ã¯ãã€ã
ã€ãã€ã»ãªãã»ã¢ã»ãã€ãŠãŒã¬ãã€ãã¯ã»ãšã€ãž
ãšã³ãïŒThe Influence of Dosage Ferm on
the Activity of ïœ Diuretic AgentïŒã ã¯ãª
ãã«ã«ã»ãã¢ãŒãã³ããžã€ã»ã¢ã³ãã»ã»ã©ããŠãŒ
ãã€ã¯ã¹ïŒClinical Pharmacology and
TherapeuticsïŒãïŒå·»No.ïŒã598ã604é ïŒ1968ïŒ
ã«èšèŒãããŠãããäžè¬ã«ãã®ãããªåŸæ¥ã®äžå
é補å€ã¯ãçš®ã ã®çŽ°åãããæåããã¹ãŠäžç·ã«
åå¯ã«æ··åããããšã«ãã€ãŠè£œé ãããã ããããªãããåŸæ¥æäŸããããã®ãããªè€å
ç©ã«é¢ããŠæªã 解決ãããŠããªãåé¡ã®äžã€ã¯ã
è€åçµæç©ãæ£è ã«äžå®å®ã§äžå®å šã«ããåžåã
ãããæåã®æ¯èŒçã«äœããã€ãªã¢ãã€ã©ããªã
ã€ããçããªãããšã§ããããã®ããšããæ£è ã«
å¿ èŠãªããªã¢ã ãã¬ã³ã®èŠæãã®éãäžæçã«ãª
ããåã¯å¢å ããã ãŸããå¥ã®åé¡ãšããŠããã€ãªã¢ãã€ã©ããªã
ã€ã®æé©ãªåå³ãããã¯ãããã¢ãžãã§æ²»çäžã®
æ£è ããã®åŸãããªã¢ã ãã¬ã³âãããã¯ããã
ã¢ãžãè€åç©æ²»çã«ç§»ããŠäœã«ãªãŠã è¡çãæå¶
ããè©Šã¿ãããå Žåã«ãé«è¡å§åã¯æµ®è «ã®æå¹ãª
æå¶ãæ倱ããå±éºããã€ãããããã¯ãããã¢
ãžãã®ä»¥åã«ã¯èš±å®¹ãããæå¹ã§ãã€ãæäžéã¯
ãã€ãªã¢ãã€ã©ããªãã€ã®äœäžã«ãã€ãŠçžå¯Ÿçã«
äžé©åœã«ãªããæŽã«ãäœã«ãªãŠã è¡çã®æå¹ãªæ
å¶åã¯å埩ãèªããããªãã€ãããã®ãããªå°é£
ã¯ãæžæ¿æ¶²ãåã¯åå¥ã®é å€è¥ããã¯ã«ãã»ã«äž
ã®æŽ»æ§æåã®åå¥ã®åºäœæäžéãæäžããããšã«
ãã€ãŠå æããããšèãããããããããªããã
ãã®ãããªã¢ãããŒãã¯äžè¬ã«ãæ®ã«ãé©åã«åŠ
æ¹ãããæè¬éãåžžã«æåããããšã«æ£è ã®æ¿è«Ÿ
ãèŠããã®ã§ãæãŸãããªãã åŸã€ãŠããããã¯ãããã¢ãžãåã³ããªã¢ã ã
ã¬ã³ã®æ§è³ªåã³å»åŠçå©ç¹ã䞊ã³ã«äž¡è ãçµã¿å
ãããŠæäžããããšããçããäºæž¬ãããå©ç¹ã¯
é·ãç¥ãããŠããããåæåãæé©ãªãã€ãªã¢ã
ã€ã©ããªãã€ã瀺ããé«ãå®å šæ§åã³è¬åŠçå¹æ
ãæããããã«ããããã®ïŒçš®ã®ç©è³ªãé åãã
å»è¬çµæç©ãæ±ããããŠãããç¹ã«ããããã¯ã
ããã¢ãžãåã³ããªã¢ã ãã¬ã³ãå«ã¿ãå©å°¿äœçš
åã³éå§äœçšã䜵æããåç¬æäžã®ãããã¯ãã
ãã¢ãžãåã³ïŒåã¯ããªã¢ã ãã¬ã³ã®ãã€ãªã¢ã
ã€ã©ããªãã€ã«å°ãªããšãã»ãŒå¹æµããã掻æ§æ
åã®ãã€ãªã¢ãã€ã©ããªãã€ã瀺ããæå°çžå¯Ÿé
ã®ããªã¢ã ãã¬ã³ã䜿çšããŠãããã¯ãããã¢ãž
ãèªçºäœã«ãªãŠã è¡çãæå¶åã¯å埩ããäžåé
åºäœæäžçµæç©ãæ±ããããŠããã çºæã®æŠèŠ æ¬çºæã¯ãçŸåšå¥œãŸããæ æ§ã§ããããã¯ãã
ãã¢ãžãåã³ããªã¢ã ãã¬ã³ã®äž¡æ¹ãå«ã¿ãç¹ã«
åºäœã®å€åœ¢ã§ãããæé©ã®ãã€ãªã¢ãã€ã©ããªã
ã€ã®ç¹æ§åã³æ§è³ªãæããäž¡æåã®ããåäžãªåž
åæ§ãæããæå°çšéã®ããªã¢ã ãã¬ã³ã§äœã«ãª
ãŠã è¡çãæå¶åã¯å埩ããªããæé©ãªå©å°¿åã³
éå§æŽ»æ§ãçºæ®ãããå»è¬çµæç©ãæäŸãããã®
ã§ããã åŸã€ãŠãæ¬çºæã®ç®çã¯ããããã¯ãããã¢ãž
ãåã³ããªã¢ã ãã¬ã³ãçµã¿åãããŠå«ã¿ãäžæ
æãªäœã«ãªãŠã è¡å¯äœçšãæå¶åã¯å埩ããªãã
éå§âå©å°¿å€ãšããŠäœ¿çšããã®ã«é©åãããå®å š
ãã€æå¹ãªå»è¬çµæç©ãæäŸããããšã«ããã æ¬çºæã¯ãæŽã«ãå°ãªããšãïŒçš®ã®æŽ»æ§æåã
å«ã¿ãå°ãªããšãäžæ¹ã®æåãççåŠç液äœã«ã
ã溶ãã«ãããèããç°ãªãçæ°Žæ§åã³ïŒåã¯èŠª
æ°Žæ§ãæããè¬å€ã®ãã€ãªã¢ãã€ã©ããªãã€ãå
äžããççåŠçåžåæåã®äžæ§æ§ãå¢å ããŠãã
å»è¬çµæç©ã®è£œé æ¹æ³åã³çæããçµæç©ãæäŸ
ããããšãç®çãšããã æ¬çºæã®æŽã«ç¹æ®ãªç®çã¯ããããã¯ãããã¢
ãžãåã³ããªã¢ã ãã¬ã³ãå«ã¿ããã®çµæç©ã®æŽ»
æ§æåãåäžã«åžåãããåå³ãããã¯ãããã¢
ãžãåã¯åå³ããªã¢ã ãã¬ã³æäžã«ãã€ãŠçãã
ãã®ã«å¹æµããé«ããã€ãªã¢ãã€ã©ããªãã€ãç
ããå»è¬çµæç©ã®è£œé æ¹æ³ãçæããå»è¬ããã³
ãã®äœ¿çšæ¹æ³ãæäŸããããšã«ããã æ¬çºæã®æŽã«å¥ã®ç®çã¯ãé åããæå°éã®ã
ãªã¢ã ãã¬ã³ã䜿çšããªãããããã¯ãããã¢ãž
ãèªçºäœã«ãªãŠã è¡çãæå¶åã¯å埩ããããšã®
ã§ããçµæç©åã³é¢é£ããæ¹æ³ãæäŸããããšã«
ããã äžè¬ã«ãæ¬çºæã®ç¬¬äžã®ç¹å¥ãªç®çã¯ãæå°é
ã®ããªã¢ã ãã¬ã³ã䜿çšããæå¹ãªãã€ãªã¢ãã€
ã©ããªãã€ãçãããããã¯ãããã¢ãžãèªçºäœ
ã«ãªãŠã è¡çãåé¿åã¯æå¶åã¯å埩ããçµç©ã
æäŸããããšã§ãããäžè¬ã«ãäœã«ãªãŠã è¡çã¯
çŽ3.5mEgïŒïŒ¬ä»¥äžã®è¡æž ã«ãªãŠã æ¿åºŠã§ååšã
ããšèããããã æ¬çºæã®ãããã®åã³ä»ã®ç®çãäžèšã®è©³çŽ°ãª
説æããæããã«ããã æå©ãªæ æ§ã®èª¬æ æ¬çºæã®å¥œãŸããå®æœæ æ§ã«ãããŠã¯ãããã
ã¯ãããã¢ãžãïŒïŒâã¯ããâïŒïŒïŒâãžããã
â2HâïŒïŒïŒïŒïŒâãã³ãŸãã¢ãžã¢ãžã³âïŒâ
ã¹ã«ãã³ã¢ããâïŒïŒïŒâãžãªãã·ãïŒãããªã¢
ã ãã¬ã³ïŒïŒïŒïŒïŒïŒâããªã¢ããâïŒâããšã
ã«ãããªãžã³ïŒãåã³è¬åŠçã«èš±å®¹ãããç¡æ¯æ§
æ æç©è³ªåã¯ææã®è¬çäœçšãçããä»ã®ç©è³ªãš
çµã¿åãããã æ¬çºæã®å»è¬çµæç©ã®è£œé æ¹æ³ã®å¥œãŸããå®æœ
æ æ§ã¯ãããªã¢ã ãã¬ã³åã³ãããã¯ãããã¢ãž
ãããããªã¢ã ãã¬ã³ïŒãããã¯ãããã¢ãžãã®
çŽ1.75ã1.25ïŒïŒã®ééæ¯ã§æºåããå·¥çšãå«
ãããããã®æåãå¥ã ã«ããããã®ãã€ãªã¢ã
ã€ã©ããªãã€ã®åäžã«å¯äžããä»å çæ æç©è³ªãš
æ··åãããããããã®æ··åç©ãé ç²ããåŸã«ãçµ
ã¿åãããæ··åãããçããå»è¬çµæç©ã¯åºäœã®
å€åœ¢ã§ãç¹ã«é å€åã¯ã«ãã»ã«ãšããŠæäŸããã®
ã奜ãŸããã ããªã¢ã ãã¬ã³ã®éã¯ãééåºæºã§ããããã¯
ãããã¢ãžãã®éã®çŽ1.75ã1.25åã®ç¯å²ã§ãã
ããçŽ1.5ïŒïŒã§ããã®ããæå©ãã€æã奜ãŸã
ããçšèªãããªã¢ã ãã¬ã³ééåºæºãã¯ã以äžã«
ãããŠãããªã¢ã ãã¬ã³ã®éã«å¯Ÿããå¥ã®æåã®
éïŒééåºæºïŒã®æ¯ãè¡šããã®ãšããã ããªã¢ã ãã¬ã³æåèªäœã¯åŸ®çŽ°ã«ç²ç ããã圢
ã§ã奜ãŸããã¯å°ãªããšãçŽ95ïŒ ã200ã¡ãã·ãŠ
ã®ç¯©ãééããçšåºŠã§ããããããçŽ25ã75ïŒ
ïŒããªã¢ã ãã¬ã³ééåºæºã§ïŒã奜ãŸããã¯çŽ35ã
55ïŒ ã®ãŠã€ããã³ã°å€ãäŸãã°ç²æ«ã»ã«ããŒã¹ã
N.F.ãïŒC6H10O5ïŒoãå«ã第äžã®æ··åç©ã«ããã
ãšãã§ãããé©åœãªãŠã€ããã³ã°å€ã¯ã¡ã³ãã«ç€Ÿ
ïŒMendell Co.ïŒããåååãã¬ã¯ã»ã«
ïŒREXCELïŒããçŸåšã¯ãœã«ã«ãŒãããã¯
ïŒSOLKAâFLOKïŒBWâ100ãã§åžè²©ãããŠã
ããã®ãåã¯ã·ãã³ã»ã±ãã«ã«ç€Ÿ
ïŒSitcoChemicalïŒããåååããšã¯ã¹âã»ã«
ïŒEXâCELïŒãã§åžè²©ãããŠãããã®ã§ãããã
ã®ãããªãŠã€ããã³ã°å€ã¯ãæ°Žæ§ççåŠç液äœã«
觊ãããšãã«ãåŸã«åœ¢æãããé¡ç²ïŒä»¥äžåç §ïŒ
å ã«æ°ŽãåžåŒããŠèšæœ€ããé¡ç²ãç Žå£ããã®ã«æ
å¹ã§ããã¹ãã§ããããã®ç©è³ªã¯çµæç©äžã§åžã
äžãäœçšãé«ããããã«ãçŽ200ã¡ãã·ãŠã®ç¯©ã
ééãããã倧ãã瞊ã®å¯žæ³ãæããã®ãæå©ã§
ããã ãã®æ··åç©ã«æŽã«çŽ20ã240ïŒ ïŒããªã¢ã ãã¬
ã³ééåºæºïŒã奜ãŸããã¯çŽ150ã190ïŒ ã®çŽ°åã
ããçµåå€â厩å£å€ãäŸãã°åŸ®æ¶æ§ã»ã«ããŒã¹ã
N.F.ïŒC6H10O5ïŒoãæ·»å ãããé©åœãªçµåå€â厩
å£å€ã¯ãFMCã³ãŒãã¬ã€ã·ãšã³ããåååãã¢
ãã»ã«ïŒAVICELïŒPHâ102ãã§åžè²©ãããŠã
ããã®ã§ãããé©åœãªæ¹¿æœ€å€ãäŸãã°ã©ãŠãªã«ç¡«
é žãããªãŠã ãããã·ã«ç¡«é žãããªãŠã CH3
ïŒCH2ïŒ10CH2OSO3Naããããªã¢ã ãã¬ã³ééåº
æºã§çŽïŒã10ïŒ ã奜ãŸããã¯çŽïŒãïŒïŒ ã®éã§æ·»
å ããããšãã§ãããé©åœãªç©è³ªã¯ãåååãã
ãããã€ãã¯ã¹ïŒMaprofixïŒãïŒãªããã¯ã¹ã»ã±
ãã«ã«ç€ŸïŒOnyx Chemical Co.ïŒãã®äžã«åžè²©ã
ããŠããã ä»ã®è¬åŠçã«èš±å®¹ããããäžæŽ»æ§ãªç¡æ¯æ§æ æ
ç©è³ªãæŽã«ååšããŠãããããããã®æåããã¹
ãŠäžç·ã«æ··åããŠç¬¬äžã®æ··åç©ã補é ãããè¬åŠ
çã«äžæŽ»æ§ãªç©è³ªãšããŠãã®ãããªç¬¬äžæ··åç©äž
ã«å«ãã§ããŠããä»å çæåã¯ããã¹ãŠçŽ°åãã
ã圢ã§ããªã¢ã ãã¬ã³ééåºæºã§çŽïŒã22ïŒ ã奜
ãŸããã¯çŽ10ã18ïŒ ã®éã®åŽ©å£å€ãäŸãã°ã¯ãã¹
ã«ã«ã¡ãâã¹ãããªãŠã ãN.F.ïŒäº€åçµåããã
ããªãŠã ã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ç©è³ªïŒã§ã
ã€ãŠãããé©åœãªç©è³ªã¯åååãAcâDiâSolã
ïŒFMCã³ãŒãã¬ã€ã·ãšã³ïŒåã³ãCLDããããã±
ã€ã»ã»ã«ããŒã¹ç€ŸïŒBukeye Cellulocse Corp.ïŒã
ã®äžã§åžè²©ãããŠãããã®ã§ããã ãã®ç¬¬äžæ··åç©ã«ééåºæºã§çŽïŒã12ïŒ ã奜ãŸ
ããã¯çŽïŒã10ïŒ ã®éã®è£œå€æ»æ²¢å€ãäŸãã°ã¹ã
ã¢ãªã³é žãã°ãã·ãŠã ãšã©ãŠãªã«ç¡«é žãããªãŠã
ã®æ··åç©ïŒåè ã®94éééšåã³åŸè ã®ïŒéééšã
æºåãã奜ãŸããã¯æå湿åŒæ··åãã次ã«ä¹Ÿç¥
ããããªã³ã°ããŠè£œé ïŒãæ·»å ãããããã®æ··å
ç©ã¯ãäŸãã°ã¹ãã¢ãªã³é žãã°ãã·ãŠã ãN.F.
ïŒãªã¯ã¿ãã«ã³é žãã°ãã·ãŠã å¡©Mg
ïŒC18H35O2ïŒ2ïŒ94éšåã³ã©ãŠãªã«ç¡«é žãããªãŠã
N.F.ïŒããã·ã«ç¡«é žãããªãŠã CH3
ïŒCH2ïŒ10CH2OSO3NaïŒïŒéšããæããããã®çš®
ã®é©åœãªæ»æ²¢å€ã¯ãåååãStearâïŒâWet
ïŒãã®äžã«åžè²©ãããŠãããã®ã§ãããæŽã«ãé©
åœãªæµåæ§åäžå€ãäŸãã°ã³ãã€ãç¶äºé žåçªçŽ
ãããªã¢ã ãã¬ã³ééåºæºã§çŽïŒãïŒïŒ ã奜ãŸã
ãã¯çŽ2.5ãïŒïŒ ã®éã§å ããããšãã§ãããé©
åœãªç©è³ªã¯åååãCabâïŒâSilãããã€ãã
ãã»ã³ãŒãã¬ã€ã·ãšã³ïŒCabot CorporationïŒå
ã³ãã¢ãšã·ã«ïŒAerosilïŒãïŒãã°ããµç€Ÿ
ïŒDegussaïŒInc.ïŒãã®äžã«åžè²©ãããŠãããã®ã§
ããã 以äžã«ãããŠãçšèªããããã¯ãããã¢ãžãé
éåºæºãã¯ãããã¯ãããã¢ãžãã®éã«å¯Ÿããå¥
ã®æåã®ãééåºæºã§ã®éã®æ¯ã瀺ãã 现åããããããã¯ãããã¢ãžãã奜ãŸããã¯
å°ãªããšã95ïŒ ã100ã¡ãã·ãŠã®ç¯©ãééããã
ããã¯ãããã¢ãžããçŽ120ã240ïŒ ïŒãããã¯ã
ããã¢ãžãééåºæºã§ïŒã奜ãŸããã¯çŽ160ã200
ïŒ ã®é©åœãªçµåå€â厩å£å€ãäŸãã°åŸ®æ¶æ§ã»ã«ã
ãŒã¹ãN.F.ïŒåèšïŒãåã³ãããã¯ãããã¢ãžã
ééåºæºã§çŽïŒã16ïŒ ã奜ãŸããã¯çŽ10ã12ïŒ ã®
厩å£å€ãäŸãã°ã¯ãã¹ã«ã«ã¡ããŒã¹ãããªãŠã ã
N.F.ïŒåèšïŒãåã³ãããã¯ãããã¢ãžãééåº
æºã§çŽ0.5ãïŒïŒ ã奜ãŸããã¯çŽïŒãïŒïŒ ã®æµå
æ§åäžå€ãäŸãã°ã³ãã€ãç¶äºé žåçªçŽ ãN.F.
ïŒSiO2ïŒãåã³ãããã¯ãããã¢ãžãééåºæºã§
çŽ0.5ãïŒïŒ ã奜ãŸããã¯çŽïŒãïŒïŒ ã®éã®æ»æ²¢
å€ãäŸãã°ã¹ãã¢ãªã³é žãããªãŠã ïŒã©ãŠãªã«ç¡«
é žãããªãŠã ïŒ94ïŒïŒïŒãæ··åããããšã«ãã€ãŠ
第äºã®æ··åç©ãäœããé©åœãªæµåæ§åäžå€ã¯åå
åãCabâïŒâSilãïŒãã€ãããã»ã³ãŒãã¬ã€ã·
ãšã³ïŒåã³ãã¢ãšãã·ã«ãïŒãã°ããµïŒã®äžã§åž
販ãããŠãããã®ã§ããã ããããã®æŽ»æ§æååã³æ æç©è³ªããæããå¥
å¥ã«è£œé ããïŒçš®ã®æ··åç©ã®ããããããå åã«
æ··åããå¿ èŠã«å¿ããŠãæçšãªè¬åŠççšéã«æé©
ãªç²åŸã«æŽã«ããªã³ã°ããã ãããã®ïŒçš®ã®æ··åç©ã次ã«ããããå¥ã ã«ã
åæ··åç©ã®é¡ç²ã補é ããããã«å§çž®ããããã®
åå¥ã®å§çž®å·¥çšã«ããåæ··åç©ã®å§çž®ç©è³ªè€åç©
ããäŸãã°åã ã®æŽ»æ§æåç²åãåèšã®æ·»å ç©ç²
åãšã®ãå®è³ªçã«åäžãªåå¯ãªç©ççæ··åç©ãšã
ãŠååšããããã«å€§ãããã€ã¹ã¯åã¯ã·ãŒãã®åœ¢
ã§åœ¢æããã 次ã«ãå§çž®ç©è³ªãå¥ã ã«çŽç æäœã«ä»ããŠç²åœ¢
ã«åå²ããåæ··åç©ã®ããããã®é¡ç²ãå掻æ§æ
ååã³åèšã®çš®ã ã®æ·»å å€ããæãããã«ããã
å§çž®ç©ããããããŠåœ¢æããé¡ç²ã¯é©åãªæ§é ç
äžäœæ§ãæããäžèšã®æäœã§ç¹å®ã®ç©äœãšããŠå
åšãã¹ãã§ããã æ¬çºæã®å¥œãŸããå®æœæ æ§ã§ãïŒçš®ã®ãããã
ã®æ··åç©ãå¥ã ã«åŠçããéã«ãæ··åç©ããã€ã
ããã«ïŒFitzmillïŒãNo.00篩ã«éãã®ã奜ãŸããã
æ··åç©ãå¥ã ã«å§çž®ããåŸãæ··åç©ãçŽç ããŠ
åã ã®æ··åç©ã®ããããé¡ç²ã圢æããé ç²ãã
ç©è³ªãã«ãã»ã«ã«ã¯ãã€ãããã«No.ïŒç¯©ãé å€ã«
ã¯ãã€ãããã«No.2Aã«éãããããã®ç®çã§ã
å¿è«ãåçãªæ©èœã®ä»ã®è£ 眮ã䜿çšããããšãã§
ããã ããããŠåœ¢æããé¡ç²ã¯ãïŒmmãã倧ãããã®
ãïŒïŒ 以äžã§ããã0.075mmããå°ãããã®ã20
ïŒ ä»¥äžã§ãããç¹ã«ã«ãã»ã«å€ãäœãã¹ãå Žåã«
ã¯ã1.5mmãè¶ãããã®ãïŒïŒ 以äžã§ããç²åŸç¯
å²ãæããã¹ãã§ããã ãã®åŸã第äžåã³ç¬¬äºã®ããããŠåœ¢æããé¡ç²
ãäžç·ã«æ··åããŠç¬¬äžã®è€åæ··åç©ã«ãããæ¬çº
æã®å¥œãŸããå®æœæ æ§ã§ã¯ã第äžã®æ··åç©ã«æŽã«
æ»æ²¢å€ãäŸãã°ã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠ
ãªã«ç¡«é žãããªãŠã ïŒäŸãã°94ïŒïŒééæ¯ïŒã®æ··
åç©ïŒå¥œãŸããã¯æ¹¿åŒæ··åãã也ç¥ããããªã³ã°
ããïŒãæ··åãããæ»æ²¢å€ã¯ïŒçš®ã®æ··åç©ã®åèš
æ··åééã®çŽ0.2ã1.0ïŒ ã奜ãŸããã¯çŽ0.4ã0.7
ïŒ ã§ãã€ãŠãããè€åçµæç©ãæçµçã«ã«ãã»ã«
å€ã«ããå Žåãé©åœãªå®å®å€ãè¡šé¢æŽ»æ§å€åã³æ
èå€ãååšããŠããããé å€ãäœãå Žåã«ã¯ãç
è²å€ãäŸãã°ïŒ€ïŒïŒ£ã€ãšããŒïŒyellowïŒïŒ10ã¢
ã«ãããŠã ã¬ãŒããå¿ èŠã«å¿ããŠé©åœãªçè²éã§
æ·»å ããããšãã§ããã åèšæ¹æ³ã§è£œé ãããé ç²ããæ··åããè€åçµ
æç©ãäžåé補å€ãäŸãã°é å€åã¯ã«ãã»ã«å€ã«
ããããšãã§ããã æ¬çºæã®å¥œãŸããå®æœæ æ§ã§ã¯ãè€åæ··åç©ã®
æçµçäžåé補å€ã¯ããããã¯ãããã¢ãžããçŽ
25mgã100mgã®éã§å«ãã§ããŠãããæãŸããã¯
掻æ§å»è¬æåãå³ã¡ããããã¯ããããžãåã³ã
ãªã¢ã ãã¬ã³ã®åèšééãçŽ62.5mgã25mgã«ãªã
çšåºŠã§å«ãã§ããŠãããäŸãã°1.5ïŒïŒã®ééæ¯
ã§ã¯ãããªã¢ã ãã¬ã³ïŒãããã¯ãããã¢ãžãã®
äžåéåã¯37.5ïŒ25mgã75ïŒ50mgåã¯150ïŒ100mg
ã§ãã€ãŠããã極ããŠæå¹ãªééæ¯ã¯75ïŒ50ã§ã
ãããšãå€ã€ããäžè¬ã«ãäžæ¥åœããã®ããªã¢ã
ãã¬ã³ã®æ£è ã®ç·æ¶è²»éãçŽ150mg以äžã«ãäžæ¥
åœããã®ãããã¯ãããã¢ãžãã®ç·æ¶è²»éãçŽ
100mg以äžã«éå®ããã®ãæãŸãããïŒæ¬æ现æžã«
ãããŠçšèªãæ£è ãã¯äººéãå«ããŠåç©çã®æå¡
ãè¡šãããã®ãšããïŒã é«ããã€ãªã¢ãã€ã©ããªãã€ã«å¯äžããæ¬çºæ
ã®äž»ãªç¹åŸŽã®äžã€ã¯ããã®è€åçµæç©ã®çæãã
ïŒåé補å€ãççåŠç液äœã®ååšã§äºã圢æãã
åã ã®é¡ç²ã«è¿ éã«åŽ©å£ãããèœååã³ãã®åŸã«
ããããã®é¡ç²ããã®æ¶²äœäžã§æŽã«å°ããç²ç¶æ
åã«ç Žå£ããèœåã«é¢ããããã®ããšã¯ãçžå¯Ÿç
ç²åŸã®ç¹å®ã®èª¿ç¯ãçæ°Žæ§ç©è³ªåã³èŠªæ°Žæ§ç©è³ªã
å¥ã ã«é ç²ããåŸã«åããŠæ··åããããšãåã³ã
奜ãŸããå®æœæ æ§ã§ãç¹ã«çæ°Žæ§æåãšãšãã«ã
ãŠã€ããã³ã°å€ã䜿çšããããšã«ãã€ãŠéæãã
ãã ïŒã€ã®äŸå€ã¯ããããäžè¬ã«ãæ¬çºæã®å¥œãŸã
ãå®æœæ æ§ã§ã¯ã第äžåã³ç¬¬äºæ··åç©ã«é åãã
åºçºåæã®ã»ãšãã©ããçŽ95ïŒ ã200ã¡ãã·ãŠç¯©
ãééããç²åŸãæãããæå¹ãªåžãäžãäœçšã
æäŸããïŒæ°Žåãäžåé補å€å éšã«æµžéãããïŒ
ããã«ã¯ããŠã€ããã³ã°å€ã¯200ã¡ãã·ãŠã®ç¯©ã
ééãããã倧ãã瞊æ¹åã®å¯žæ³ãæããã§ãã§
ãããïŒçžå¯Ÿçã«èŠªæ°Žæ§ã®ïŒãããã¯ãããã¢ãž
ãç²åã¯ã95ïŒ ã200ã¡ãã·ãŠã®ç¯©ãééãã¹ã
ã§ããããçŽ95ïŒ ã100ã¡ãã·ãŠã®ç¯©ãééãã
ãã®ã§ãã€ãŠããããå¥ã ã«è£œé ãããæ··åç©äž
ã®æååã³æ æç©è³ªã®ç²åŸã¯ããã®åŸã«åœ¢æãã
ãé¡ç²ã®ç²åŸããå°ãªããšãïŒæ¡ä»¥äžå®è³ªçã«å°
ãããã¹ãã§ããã 掻æ§æåã®ãã¡ããããã¯ãããã¢ãžãã¯çžå¯Ÿ
çã«èŠªæ°Žæ§ã§ãããããªã¢ã ãã¬ã³ã¯çžå¯Ÿçã«ç
æ°Žæ§ã§ãããåèšã®ããã«ãåŸæ¥ã®ç©è³ªåã³çµæ
ç©ãçšããå Žåã«èµ·ããåé¡ã®äžã€ã¯ãåºäœè£œå€
ïŒåã³åéç©ïŒã®è¡šé¢ã«ããªã¢ã ãã¬ã³ã®åŸ®çŽ°ãª
ç²åããããåäžã«ååšããããã«ããæ°Žåã®æµž
éã«å¯Ÿããçæ°Žæ§éå£ãäœãããšã§ãã€ããšèã
ãããã®çŸè±¡ã®èµ·ããåå ã¯ãæããã«ãïŒçš®ã®
掻æ§æååã³ä»ã®åžžçšã®æé åã¯ã«ãã»ã«åœ¢ææ·»
å ç©ããã¹ãŠçŽ°åããã圢ã§ãäºãå¥åã®çµæç©
ãé¡ç²ã«ããããšãªããäžç·ã«æ··åããããšã§ã
ããããããŠæ°Žåã¯ãããã¯ãããã¢ãžããšæ¥è§Š
ããªãããåã¯æ¥è§Šãæå¶ããããåŸã€ãŠã補å€
ã¯è¿ éã«åŽ©å£ããããã®çµæããã®ãããªçµæç©
ã¯éããããäžå®å®ãªãã€ãªã¢ãã€ã©ããªãã€ã
瀺ãããšã«ãªãã ããã«åããŠãæ¬çºæã«ããã°ã掻æ§æåãæ··
åããåã«ä»ã®ç©è³ªãšå ±ã«å¥ã ã«é ç²ããã®ã§ã
çæ°Žæ§ç²ç¶ç©è³ªåã³èŠªæ°Žæ§ç²ç¶ç©è³ªã¯çžäºã«åé¢
ããŠããŠãããã«ããåèšã®ãããªè¡šé¢äœçšã¯å
é¿ãããåºäœè£œå€ã®äºå圢æé¡ç²ãžã®åŽ©å£ãä¿é²
ããããã®é¡ç²èªäœãè¿ éã«åŽ©å£ããŠæŽ»æ§æåã®
埮现ãªç²åãåæ£ãããããšãã§ããããã®å¹æ
ã¯ãããããã®é¡ç²ãç²ç ããŠç²åã®é²åè¡šé¢ç©
ãå¢å ããïŒããã«ãã溶解é床ãå¢å ããïŒã
ãšã«ãã€ãŠæŽã«åäžããã 以äžã«ç€ºãããã«ãããªã¢ã ãã¬ã³æåã®æº¶è§£
æ§åã³ãã€ãªã¢ãã€ã©ããªãã€ããæ¬çºæã®é¡ç²
ã®åœ¢ã§ååšããå Žåã«åäžããã æ¬çºææ¹æ³ã¯ãèªäœçžäºã«æ¬è³ªçã«åäžãªãã
ãããã®æåã®å¥ã ã®é¡ç²ã圢æããããæçµç
çµæç©ã«ãããŠã¯ãããšãªãé¡ç²ãäžç·ã«æ··åã
ããŠããç¹ã§äžåäžã§ãããæŽã«ãéçžæº¶æ§ã®å
é¡ãåé¿ããªããæçµç溶解æ§ãåäžããããã
ã«ãå¿ èŠã«å¿ããŠãçš®ã ã®æŽ»æ§æåãšå ±ã«ãç°ãª
ã補å€æ·»å ç©ã䜿çšããããšãã§ããã æ¬æ现æžã«ãããŠããç°çš®é¡ç²ããšã¯ãåã ã«
å¥åã®é¡ç²ãååšããäžæ¹ã®é¡ç²ãããªã¢ã ãã¬
ã³æåãå«ã¿ãä»æ¹ã®é¡ç²ããããã¯ãããã¢ãž
ããå«ãããšãæå³ãããåŸã€ãŠããã®çšèªã¯ã
å§ãã«ããªã¢ã ãã¬ã³åã³ãããã¯ãããã¢ãžã
ã®äž¡æ¹ãå«ãé¡ç²ã圢æããçµæç©ã«é¢ããŠã¯äž
é©åã§ãããçšèªãç°çš®é¡ç²ãã¯ãåãåã ã«è£œ
é ããé¡ç²ãæ··åããåŸãåã³äžç·ã«å§çž®ããã
åã¯å¡ç¶ã«ããŠæé ãã«ãã»ã«å€åœ¢æçã®ããã®
æ¯èŒç倧ããè€åé¡ç²ã圢æããå Žåã«ããæ¬çº
æã«ã¯é©åã§ããã ãã€ãªã¢ãã€ã©ããªãã€ãå¢å ãã第äºæ®µéã¯
äºã圢æããåã ã®é¡ç²ãççåŠçã«ãªãå°ãã
æåã«ç Žå£ããããšã§ããããŠã€ããã³ã°å€ã䜿
çšããããšã«ãã€ãŠãæ°Žåã¯é¡ç²ã®å éšã«åžåŒã
ããé¡ç²ãèšæœ€ããããŸãã厩å£å€åã³è¡šé¢æŽ»æ§
å€ããã®ãããªææã®ç Žå£ã«å¯äžããã æ¬çºæã®ãã®å®æœæ æ§ã®å©ç¹ã®äžã€ã¯ãããã
ãã®æŽ»æ§æåãç¬ç«ã«åèšã®å»è¬æ æç©è³ªãšæ··å
ããŠå¥ã ã®é¡ç²ãäœã€ãŠãç²åŸã®åŸ®çŽ°ãªæŽ»æ§æå
ãçµã¿åãããŠäœ¿çšããããšã«ãã€ãŠãé«ããã€
ãªã¢ãã€ã©ããªãã€ãéæã§ããçµæãšããŠãã
ãªã¢ã ãã¬ã³ã®äœçšã«ãããããã¯ãããã¢ãžã
èªçºäœã«ãªãŠã è¡çãæå¶åã¯å埩ãããããšã§
ãããçæ°Žæ§ãããã¯ãããã¢ãžãé¡ç²ã¯ããã®
ãããªé¡ç²ã®ç Žå£ãè£å©ãããããŠã€ããã³ã°å€
ãå«ãã§ããã®ã奜ãŸããã芪氎æ§ãããã¯ãã
ãã¢ãžãé¡ç²ã¯ãæ¬çºæã®é å€åã¯ã«ãã»ã«å€ã®
圢ã§ãã€ãŠããæ°Žåã¯ä»ã®äœæ¶²ã容æã«åžåãã
åºäœè£œå€ã®é©åãªç Žå£ãä¿é²ããŠé¡ç²ã«ãããé¡
ç²ã¯ã次ã«ã奜ãŸããã¯åŽ©å£å€ã湿最å€åã³ããª
ã¢ã ãã¬ã³é¡ç²äžã®ãŠã€ããã³ã°å€ã«ãã€ãŠå©æ
ãããŠåŽ©å£ããã å®æœäŸ äžèšã®å®æœäŸåã³ããŒã¿ã¯æ¬çºæã®æ¹æ³åã³çµ
æç©ãæŽã«èª¬æãããã®ã§ããã äŸ ïŒ ããªã¢ã ãã¬ã³ïŒãããã¯ãããã¢ãžãã®éé
æ¯ã1.5ïŒïŒã§ããæ¬çºæã®å»è¬çµæç©50Kgã補
é ãããããäžèšã®æäœã䜿çšããã ããªã¢ã ãã¬ã³ïŒç±³åœè¬å±æ¹ïŒçŽ9.38KgããŠã€
ããã³ã°å€4.75Kgãçµåå€â厩å£å€15.6Kgã厩å£
å€1.25Kgã湿最å€åã¯è¡šé¢æŽ»æ§å€ãäŸãã°ã©ãŠãª
ã«ç¡«é žãããªãŠã 500ïœãã¹ãã¢ãªã³é žãã°ãã·
ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒ750ïœ
åã³æµåæ§åäžå€250ïœãå«ã第äžæ··åç©ã補é
ããã 厩å£å€ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«
ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒåã³æµåæ§åäžå€æå
ãäºãå åæ··åããããã®äºåæ··åç©ã次ã«30ã¡
ãã·ãŠã®ç¯©ã«éããããªã¢ã ãã¬ã³ãçµåå€â厩
å£å€åã³ãŠã€ããã³ã°å€æåã篩ã§ç¯©éãããæ
åãå šéšã0.14m3ïŒ5ft3ïŒã®ïŒ¶åãã¬ã³ããŒã«å ¥
ããçŽ15åæ··åãããæ··åããç©è³ªã次ã«ãé«
éãè¡ææšé²ãã€ãããã«No.00ã¹ã¯ãªãŒã³ã«é
ããããããŠããªã³ã°ããæ··åç©ããã®åŸå¡ç¶ã«
ããããåã¯å§çž®ããŠç¬¬äžæ··åç©ã®é¡ç²ã«ããã
å¡ç¶ååã¯å§çž®ã«ããã1inåœããçŽïŒãïŒãã³
ã®å§åã䜿çšããŠãçŽåŸçŽ1.27cmïŒ1/2â³ïŒã®ç¡¬è³ª
ãã€ã¹ã¯åã¯åãçŽ0.32cmïŒ1/8â³ïŒã®ã·ãŒãçã
圢æããããã®å§çž®ããç©è³ªã次ã«äžé床ãã€ã
æšé²ãã€ãããã«No.2Aã¹ã¯ãªãŒã³ã«éããŠç²ç
ããé¡ç²ã圢æãããã«ãã»ã«å€ã補é ãããå Ž
åã«ã¯ã第äžæ··åç©ã®é¡ç²ã補é ãããã®æçµæ®µ
éã§ãã€ãããã«No.ïŒã¹ã¯ãªãŒã³ã代æ¿äœ¿çšããŠ
ãããã 现åããããããã¯ãããã¢ãžãïŒç±³åœè¬å±
æ¹ïŒçŽ6.25Kgãçµåå€â厩å£å€10.00Kgã厩å£å€
625ïœãæµåæ§åäžå€125ïœåã³ã¹ãã¢ãªã³é žãã°
ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒ
125ïœãïŒç·ã«æ··åããŠç¬¬äºæ··åç©ã補é ããã
é å€ã補é ããå Žåã«ã¯ãçè²å€çŽ125ïœãæ·»å
ããŠãããã厩å£å€ãã¹ãã¢ãªã³é žãã°ãã·ãŠ
ã ïŒã©ãŠãªã«ç¡«é žãããªãŠã åã³æµåæ§åäžå€
ïŒäœ¿çšããçè²å€ãäžç·ã«ïŒãäºãæ··åãããŸã
30ã¡ãã·ãŠã®ç¯©ã§ç¯©éããããããã¯ãããã¢ãž
ãåã³çµåå€â厩å£å€ãäºã18ã30ã¡ãã·ãŠã®ç¯©
ã§ç¯©éããŠå¡ãé€å»ããŠãããããã®åŸã«äœ¿çšã
ãæ··åãããªã³ã°ãé ç²æäœã¯ç¬¬äžæ··åç©ã«é¢ã
ãŠäœ¿çšããã®ãšåãã§ããã ããããŠåèšã®å¥ã ã®æ··åç©ã®äžŠè¡é ç²ã«ãã€
ãŠåå¥ã«è£œé ããç²ç ããæ··åç©é¡ç²ã次ã«å¥ã
ã«é·ããïŒmmïŒæ倧寞æ³ïŒãã倧ãããã®ãçŽïŒ
ïŒ ä»¥äžã§ãé·ãã0.075mmããå°ãããã®ãçŽ20
ïŒ ä»¥äžã§ããæŠç¥ã®ç²åŸç¯å²ã«ããªã³ã°ããã 次ã«ãééåºæºã§94ïŒïŒã®æ¯ã®æ··åããã¹ãã¢
ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã
250ïœã30ã¡ãã·ãŠã®ç¯©ã«éãããããã第äžå
ã³ç¬¬äºã®æ··åç©ããæã第äžåã³ç¬¬äºé¡ç²ã次ã«
æ··åããã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«
é žãããªãŠã ãšäžç·ã«0.14m3ïŒ5ft3ïŒã®ïŒ¶åãã¬
ã³ããŒäžã§çŽ15åæ··åããã é å€ã補é ãããå Žåã«ã¯ããã®æçµæ··åç©ã
次ã«åžžçšã®æé ãã¬ã¹ã§å§çž®ããããšãã§ããã ã«ãã»ã«åºäœè£œå€ã補é ããå Žåã«ã¯ãæ··åã
ãç©è³ªãé©åãªèªåè£ çœ®ã§åã«ãã»ã«äžã«å°å ¥ã
ãããšãã§ãããã«ãã»ã«å€ã補é ããå Žåãç
è²å€ãçãããšãã§ããç²åŸã®äžéã¯é·ãã1.5
mmãè¶ãããã®ãïŒïŒ 以äžã§ããçšåºŠã§ãã€ãŠã
ãã äžåé補å€ã¯ãåèšã®æ¹æ³ã§è£œé ãã0.4ïœã®
é å€ã§ããã®ãæãŸããããã®é å€ã¯ç¬¬äžæ··åç©
ããããªã¢ã ãã¬ã³ïŒç±³åœè¬å±æ¹ïŒçŽ75mgããŠã€
ããã³ã°å€38mgãçµåå€â厩å£å€125mgã厩å£å€
10mgã湿最å€åã¯è¡šé¢å€ãäŸãã°ã©ãŠãªã«ç¡«é žã
ããªãŠã ïŒç±³åœè¬å±æ¹ïŒïŒmgãã¹ãã¢ãªã³é žãã°
ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒïŒ
mgåã³æµåæ§åäžå€ïŒmgãå«ã¿ãæŽã«ç¬¬äºæ··åç©
ãããããã¯ãããã¢ãžãïŒç±³åœè¬å±æ¹ïŒ50mgã
çµåå€â厩å£å€80mgã厩å£å€ïŒmgãæµåæ§åäžå€
ïŒmgãã¹ãã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«é ž
ãããªãŠã ïŒ94ïŒïŒïŒïŒmgåã³çè²å€ïŒmgãå«
ããæŽã«ãæçµçæ··åæäœã§æ·»å ããã®ã§ãã¹ã
ã¢ãªã³é žãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã
ïŒ94ïŒïŒïŒïŒmgãååšããã åèšã®æäœã«ãã補é ãããé å€äžã«ãããã¯
ãããã¢ãžã50mgåã³ããªã¢ã ãã¬ã³75mgãå«ã
奜ãŸããé å€ã¯ãäžèšã®ç©è³ªãäžèšã®éã§äœ¿çšã
ããã®ã§ããã
ãè¡šã
ãè¡šã
åã
ã®é¡ç²ã補é ããåŸãã¹ãã¢ãªã³é
žãã°ã
ã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒ250
ïœãæ·»å ããæçµçæ··åç©ãå åã«æ··åããåžžæ³
ã§é å€ïŒåã¯ã«ãã»ã«å€ïŒã«æ圢ããã äŸ ïŒâ é å€äžã«ãããã¯ãããã¢ãžã50mgåã³ããªã¢
ã ãã¬ã³100mgãå«ã第äºã®é å€ããäžèšã®ç©è³ª
ãäžèšã®éã§äœ¿çšããŠåèšæäœã«ãã補é ããã
ã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒ250
ïœãæ·»å ããæçµçæ··åç©ãå åã«æ··åããåžžæ³
ã§é å€ïŒåã¯ã«ãã»ã«å€ïŒã«æ圢ããã äŸ ïŒâ é å€äžã«ãããã¯ãããã¢ãžã50mgåã³ããªã¢
ã ãã¬ã³100mgãå«ã第äºã®é å€ããäžèšã®ç©è³ª
ãäžèšã®éã§äœ¿çšããŠåèšæäœã«ãã補é ããã
ãè¡šã
ãè¡šã
åã
ã®é¡ç²ã補é ããåŸãã¹ãã¢ãªã³é
žãã°ã
ã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒ300
ïœãæ·»å ããæ··åããåèšã®ããã«é å€åã¯ã«ã
ã»ã«å€ã«æ圢ããã äŸ ïŒâ ã«ãã»ã«äžã«ãããã¯ãããã¢ãžã25mgåã³ã
ãªã¢ã ãã¬ã³50mgãå«ãã«ãã»ã«å€ããäžèšã®ç©
質ãäžèšã®éã§äœ¿çšããŠåèšæäœã«ãã補é ã
ãã
ã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒïŒïŒ300
ïœãæ·»å ããæ··åããåèšã®ããã«é å€åã¯ã«ã
ã»ã«å€ã«æ圢ããã äŸ ïŒâ ã«ãã»ã«äžã«ãããã¯ãããã¢ãžã25mgåã³ã
ãªã¢ã ãã¬ã³50mgãå«ãã«ãã»ã«å€ããäžèšã®ç©
質ãäžèšã®éã§äœ¿çšããŠåèšæäœã«ãã補é ã
ãã
ãè¡šã
ãè¡šã
åã
ã®é¡ç²ã補é ããåŸãããã«ã¹ãã¢ãªã³é
ž
ãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒ
ïŒïŒ200ïœãæ·»å ããæ··åããåžžæ³ã§No.ïŒã«ãã»
ã«ã«æ圢ããã äŸ ïŒ ãããã¯ãããã¢ãžãåã³ããªã¢ã ãã¬ã³ã®å
äžãªæ··åç©ããæãåŸæ¥ã®ãçŸåšåžè²©ãããŠãã
çµæç©ãåã³ãã€ãªã¢ãã€ã©ããªãã€ã®æé©ãªå
ç §æšæºãšããŠäœ¿çšããæžæ¿æ¶²ãšæ¯èŒããŠæ¬çºæã®
çµæç©ã®ãã€ãªã¢ãã€ã©ããªãã€ã枬å®ããã
ããäžèšã®è©Šéšãè¡ãªã€ãã ããªã¢ã ãã¬ã³100mgåã³ãããã¯ãããã¢ãž
ã50mgãå«ãæ°Žæ§æžæ¿æ¶²ãïŒäººã®å»ºåº·ãªå¿é¡è ã«
æäžããããããã®åå è ã«ç°ãªãæç¹ã§ãæ¬çº
æã«ãã圢æããïŒåã®é å€ïŒããªã¢ã ãã¬ã³75
mgåã³ãããã¯ãããã¢ãžã50mgãå«ãïŒãäžã
ããä»ã®åå è ã«ãçŸåšåžè²©ãããŠããåŸæ¥ã®ã«
ãã»ã«ïŒåïŒåèšã§100mgã®ããªã¢ã ãã¬ã³åã³
50mgã®ãããã¯ãããã¢ãžããå«ãïŒä»¥åã«
FDAã§æ¿èªãããããªã¢ã ãã¬ã³ïŒãããã¯ã
ããã¢ãžãè€ååŠæ¹ïŒãäžãããæäžåŸã«ãå°¿ã
éããååãããå°¿ã®éãå®éãããããªã¢ã ã
ã¬ã³ã®å°¿ããã®ååéã®æž¬å®çµæïŒæäžåŸ72æé
ã®éã«å°¿äžã§ååãããmgæ°ïŒã第衚ã«ç€ºãã
ãã°ãã·ãŠã ïŒã©ãŠãªã«ç¡«é žãããªãŠã ïŒ94ïŒ
ïŒïŒ200ïœãæ·»å ããæ··åããåžžæ³ã§No.ïŒã«ãã»
ã«ã«æ圢ããã äŸ ïŒ ãããã¯ãããã¢ãžãåã³ããªã¢ã ãã¬ã³ã®å
äžãªæ··åç©ããæãåŸæ¥ã®ãçŸåšåžè²©ãããŠãã
çµæç©ãåã³ãã€ãªã¢ãã€ã©ããªãã€ã®æé©ãªå
ç §æšæºãšããŠäœ¿çšããæžæ¿æ¶²ãšæ¯èŒããŠæ¬çºæã®
çµæç©ã®ãã€ãªã¢ãã€ã©ããªãã€ã枬å®ããã
ããäžèšã®è©Šéšãè¡ãªã€ãã ããªã¢ã ãã¬ã³100mgåã³ãããã¯ãããã¢ãž
ã50mgãå«ãæ°Žæ§æžæ¿æ¶²ãïŒäººã®å»ºåº·ãªå¿é¡è ã«
æäžããããããã®åå è ã«ç°ãªãæç¹ã§ãæ¬çº
æã«ãã圢æããïŒåã®é å€ïŒããªã¢ã ãã¬ã³75
mgåã³ãããã¯ãããã¢ãžã50mgãå«ãïŒãäžã
ããä»ã®åå è ã«ãçŸåšåžè²©ãããŠããåŸæ¥ã®ã«
ãã»ã«ïŒåïŒåèšã§100mgã®ããªã¢ã ãã¬ã³åã³
50mgã®ãããã¯ãããã¢ãžããå«ãïŒä»¥åã«
FDAã§æ¿èªãããããªã¢ã ãã¬ã³ïŒãããã¯ã
ããã¢ãžãè€ååŠæ¹ïŒãäžãããæäžåŸã«ãå°¿ã
éããååãããå°¿ã®éãå®éãããããªã¢ã ã
ã¬ã³ã®å°¿ããã®ååéã®æž¬å®çµæïŒæäžåŸ72æé
ã®éã«å°¿äžã§ååãããmgæ°ïŒã第衚ã«ç€ºãã
ãè¡šã
ãè¡šã
ãããã®è©Šéšã¯ãæ¬çºæã®çµæç©ã«ã€ããŠã¯æ
äžéã®53.9ïŒ ã®å¹³åããªã¢ã ãã¬ã³ãã€ãªã¢ãã€
ã©ããªãã€ãçããããã¯åŸæ¥ã®ã«ãã»ã«ã«é¢ã
ãå ã23.5ïŒ ã®å¹³åå€ãšã¯å¯Ÿç §çã«ãæžæ¿æ¶²ã«é¢
ãã54.1ïŒ ã®å€ãšåçã§ããã ãã®åŸãåŸæ¥ã®ã«ãã»ã«åã³æ¬çºæã«ãã補é
ããã«ãã»ã«ïŒäŸïŒâïŒã䜿çšããŠãåã³ç¬¬äž
ã°ã«ãŒãã®ïŒäººã®å¥åº·ãªèªçºçåå è ã«ã€ããŠç¬¬
äºã®è©Šéšãè¡ãªã€ããåæ§ã«æž¬å®ããããŒã¿ã第
â衚ã«ïŒæ¯èŒã®äŸ¿å®ã®ããã第衚ã®ããŒã¿
ãšäžç·ã«ïŒç€ºãã
äžéã®53.9ïŒ ã®å¹³åããªã¢ã ãã¬ã³ãã€ãªã¢ãã€
ã©ããªãã€ãçããããã¯åŸæ¥ã®ã«ãã»ã«ã«é¢ã
ãå ã23.5ïŒ ã®å¹³åå€ãšã¯å¯Ÿç §çã«ãæžæ¿æ¶²ã«é¢
ãã54.1ïŒ ã®å€ãšåçã§ããã ãã®åŸãåŸæ¥ã®ã«ãã»ã«åã³æ¬çºæã«ãã補é
ããã«ãã»ã«ïŒäŸïŒâïŒã䜿çšããŠãåã³ç¬¬äž
ã°ã«ãŒãã®ïŒäººã®å¥åº·ãªèªçºçåå è ã«ã€ããŠç¬¬
äºã®è©Šéšãè¡ãªã€ããåæ§ã«æž¬å®ããããŒã¿ã第
â衚ã«ïŒæ¯èŒã®äŸ¿å®ã®ããã第衚ã®ããŒã¿
ãšäžç·ã«ïŒç€ºãã
ãè¡šã
ãããã第衚åã³ç¬¬ïŒ¡è¡šã«å¯Ÿå¿ããŠããã
ãã¯ãããã¢ãžãã®å°¿äžã§ã®ååéã®æž¬å®çµæ
ïŒæäžåŸ72æéã®éã«å°¿äžã«ååãããmgæ°ïŒã
第衚åã³ç¬¬â衚ã«ç€ºãã
ãã¯ãããã¢ãžãã®å°¿äžã§ã®ååéã®æž¬å®çµæ
ïŒæäžåŸ72æéã®éã«å°¿äžã«ååãããmgæ°ïŒã
第衚åã³ç¬¬â衚ã«ç€ºãã
ãè¡šã
第衚ã«ããããããã¯ãããã¢ãžãã®ãã€ãª
ã¢ãã€ã©ããªãã€ã®å¹³åïŒ ã¯ãåŸæ¥ã®å ã38.0ïŒ
ãšã¯å¯Ÿç §çã«ãæ¬çºæã®ïŒé å€ïŒçµæç©ã«ã€ããŠ
ã¯ã60.8ïŒ ã§ãããããã¯æžæ¿æ¶²ã®59.4ïŒ ã«è¿
ãã 第â衚ã«ãããŠããããã¯ãããã¢ãžãã®
å¹³åã¢ãã€ã©ããªãã€ã¯ãåŸæ¥ã®ã«ãã»ã«ã®å Ž
åãæäžéã®30.8ïŒ ã«ãããªãã€ãããæ¬çºæã®
ã«ãã»ã«ã¯51.6ïŒ ã®å¹³åãã€ãªã¢ãã€ã©ããªãã€
ãæããæ¬çºæã®é å€ã¯60.8ïŒ ã®å¹³åãã€ãªã¢ã
ã€ã©ããªãã€ãæããŠããã
ã¢ãã€ã©ããªãã€ã®å¹³åïŒ ã¯ãåŸæ¥ã®å ã38.0ïŒ
ãšã¯å¯Ÿç §çã«ãæ¬çºæã®ïŒé å€ïŒçµæç©ã«ã€ããŠ
ã¯ã60.8ïŒ ã§ãããããã¯æžæ¿æ¶²ã®59.4ïŒ ã«è¿
ãã 第â衚ã«ãããŠããããã¯ãããã¢ãžãã®
å¹³åã¢ãã€ã©ããªãã€ã¯ãåŸæ¥ã®ã«ãã»ã«ã®å Ž
åãæäžéã®30.8ïŒ ã«ãããªãã€ãããæ¬çºæã®
ã«ãã»ã«ã¯51.6ïŒ ã®å¹³åãã€ãªã¢ãã€ã©ããªãã€
ãæããæ¬çºæã®é å€ã¯60.8ïŒ ã®å¹³åãã€ãªã¢ã
ã€ã©ããªãã€ãæããŠããã
ãè¡šã
åŸæ¥ã®çæç©ãããæ¬çºæã«ãã€ãŠäœã€ãçµæ
ç©ããèããé«ãããŒã»ã³ããŒãžã®äž¡æŽ»æ§æåã
å©çšãããã æŽã«å¥ã®è©Šéšã§ãæ¬çºæïŒäŸïŒâïŒã«ããäœ
ããããªã¢ã ãã¬ã³100mgåã³ãããã¯ãããã¢
ãžã50mgãå«ãé å€ããåãïŒäººã®åå è ïŒäŸïŒ
åç §ïŒã«äžããã第衚ã第衚ã第衚åã³
第â衚ãšåæ§ã«æž¬å®ããçµæã第衚ã«ç€º
ãã
ç©ããèããé«ãããŒã»ã³ããŒãžã®äž¡æŽ»æ§æåã
å©çšãããã æŽã«å¥ã®è©Šéšã§ãæ¬çºæïŒäŸïŒâïŒã«ããäœ
ããããªã¢ã ãã¬ã³100mgåã³ãããã¯ãããã¢
ãžã50mgãå«ãé å€ããåãïŒäººã®åå è ïŒäŸïŒ
åç §ïŒã«äžããã第衚ã第衚ã第衚åã³
第â衚ãšåæ§ã«æž¬å®ããçµæã第衚ã«ç€º
ãã
ãè¡šã
ãããã®çµæã¯ãç°ãªãåŠæ¹ã®çµæç©ãçšãã
ç¬ç«ããè©Šéšãã¿ã³ãã³ããŠã ïŒTannenbaumïŒ
çèãã¯ãªãã«ã«ã»ãã¢ãŒãã³ããžã€ã»ã¢ã³ãã»
ã»ã©ããŠãŒãã€ã¯ã¹ïŒClinical Pharmacology
TherapeuticsïŒïŒå·»ãNo.ïŒã598ã604é ïŒ1968ïŒ
åç §ãã§å ±åãããŠããããã«ã100mgã®æäžã
ãå¹³åçŽ39ïŒ ãšããèè žç®¡ã®åžååã®éçã§ãã
ãšèããããŠããæ°å€ãçŽ25ïŒ è¶ãããæ¬çºæã®
é å€ã®ããªã¢ã ãã¬ã³ã®ãã€ãªã¢ãã€ã©ããªãã€
åã³åžåã®å¹³åå€ïŒ100mgãã48mgïŒã瀺ãã æŽã«ããã®äŸã¯ãããªã¢ã ãã¬ã³ïŒãããã¯ã
ããã¢ãžãã®ïŒïŒïŒã®æ¯ã®é å€ïŒç¬¬â衚åã³
第â衚ã®ã«ãã»ã«ã§ãåæ§ïŒã«ãããŠæ¬çºæ
ã®æå¹æ§ã瀺ããããããªããèšåºäžã®çç±ã§
1.75ã1.25ïŒïŒã®ç¯å²ã®æ¯ã䜿çšããã®ãããäž
å±€æå©ã§ããã åèšã®è¡šããæãããªãšãããæ¬çºæã«ãã補
é ããçµæç©ããæ¯èŒçã«äœãå€åä¿æ°ïŒC.V.ïŒ
ã«ãã€ãŠèšŒæãããããã«é«ãå¿çåäžæ§ïŒåã
æåãæžæ¿æ¶²ã®åœ¢ã§æäžããå Žåã«å¹æµããïŒã
瀺ããæŽã«ãïŒåã®é å€ïŒäŸãã°75ïŒ50ïŒãæäž
ããããšã«ãã€ãŠé©åãªããªã¢ã ãã¬ã³ïŒåã³ã
ããã¯ãããã¢ãžãïŒã¬ãã«ãå©çšãããå€æ°ã®
é å€ãåŠæ¹ããå¿ èŠã¯ãªããããªã¢ã ãã¬ã³ã®çž
察çæäžéã®åèšã¯åŸæ¥äœ¿çšãããéããå°ãª
ãã äŸ ïŒ ãããã¯ãããã¢ãžã50mgïŒæ¥ã§æ²»çäžã§äœã«
ãªãŠã è¡çïŒè¡æž K+2.9ã3.5mEqïŒïŒ¬ïŒã«ãªã€ã
é«è¡å§æ£è ã«ã€ããŠããªã¢ã ãã¬ã³çšéå¿çç¹æ§
ã枬å®ãããããè©Šéšãè¡ãªã€ãããããã¯ãã
ãã¢ãžãã«ãã€ãŠèµ·ãäœã«ãªãŠã è¡çããå埩ã
ãã®ã«å¿ èŠãªããªã¢ã ãã¬ã³ã®æå°éã枬å®ãã
ããããããã¯ãããã¢ãžã50mgïŒæ¥ãå¥åã®é
å€ã§æäžãç¶ããæŽã«ããªã¢ã ãã¬ã³ã®äžèšã®ïŒ
æ¥ã®æäžéã®ïŒã€ãè©ŠéšæéãéããŠæžæ¿æ¶²ã®åœ¢
ã§æäžããïŒïŒmgã25mgã50mgã75mgåã³100mgã
è¡æž äžã®å¹³åã«ãªãŠã æ¿åºŠïŒmEqïŒïŒ¬ïŒã第
è¡šã«ãæäžéããšã«ãŸãšããŠç€ºãã
ç¬ç«ããè©Šéšãã¿ã³ãã³ããŠã ïŒTannenbaumïŒ
çèãã¯ãªãã«ã«ã»ãã¢ãŒãã³ããžã€ã»ã¢ã³ãã»
ã»ã©ããŠãŒãã€ã¯ã¹ïŒClinical Pharmacology
TherapeuticsïŒïŒå·»ãNo.ïŒã598ã604é ïŒ1968ïŒ
åç §ãã§å ±åãããŠããããã«ã100mgã®æäžã
ãå¹³åçŽ39ïŒ ãšããèè žç®¡ã®åžååã®éçã§ãã
ãšèããããŠããæ°å€ãçŽ25ïŒ è¶ãããæ¬çºæã®
é å€ã®ããªã¢ã ãã¬ã³ã®ãã€ãªã¢ãã€ã©ããªãã€
åã³åžåã®å¹³åå€ïŒ100mgãã48mgïŒã瀺ãã æŽã«ããã®äŸã¯ãããªã¢ã ãã¬ã³ïŒãããã¯ã
ããã¢ãžãã®ïŒïŒïŒã®æ¯ã®é å€ïŒç¬¬â衚åã³
第â衚ã®ã«ãã»ã«ã§ãåæ§ïŒã«ãããŠæ¬çºæ
ã®æå¹æ§ã瀺ããããããªããèšåºäžã®çç±ã§
1.75ã1.25ïŒïŒã®ç¯å²ã®æ¯ã䜿çšããã®ãããäž
å±€æå©ã§ããã åèšã®è¡šããæãããªãšãããæ¬çºæã«ãã補
é ããçµæç©ããæ¯èŒçã«äœãå€åä¿æ°ïŒC.V.ïŒ
ã«ãã€ãŠèšŒæãããããã«é«ãå¿çåäžæ§ïŒåã
æåãæžæ¿æ¶²ã®åœ¢ã§æäžããå Žåã«å¹æµããïŒã
瀺ããæŽã«ãïŒåã®é å€ïŒäŸãã°75ïŒ50ïŒãæäž
ããããšã«ãã€ãŠé©åãªããªã¢ã ãã¬ã³ïŒåã³ã
ããã¯ãããã¢ãžãïŒã¬ãã«ãå©çšãããå€æ°ã®
é å€ãåŠæ¹ããå¿ èŠã¯ãªããããªã¢ã ãã¬ã³ã®çž
察çæäžéã®åèšã¯åŸæ¥äœ¿çšãããéããå°ãª
ãã äŸ ïŒ ãããã¯ãããã¢ãžã50mgïŒæ¥ã§æ²»çäžã§äœã«
ãªãŠã è¡çïŒè¡æž K+2.9ã3.5mEqïŒïŒ¬ïŒã«ãªã€ã
é«è¡å§æ£è ã«ã€ããŠããªã¢ã ãã¬ã³çšéå¿çç¹æ§
ã枬å®ãããããè©Šéšãè¡ãªã€ãããããã¯ãã
ãã¢ãžãã«ãã€ãŠèµ·ãäœã«ãªãŠã è¡çããå埩ã
ãã®ã«å¿ èŠãªããªã¢ã ãã¬ã³ã®æå°éã枬å®ãã
ããããããã¯ãããã¢ãžã50mgïŒæ¥ãå¥åã®é
å€ã§æäžãç¶ããæŽã«ããªã¢ã ãã¬ã³ã®äžèšã®ïŒ
æ¥ã®æäžéã®ïŒã€ãè©ŠéšæéãéããŠæžæ¿æ¶²ã®åœ¢
ã§æäžããïŒïŒmgã25mgã50mgã75mgåã³100mgã
è¡æž äžã®å¹³åã«ãªãŠã æ¿åºŠïŒmEqïŒïŒ¬ïŒã第
è¡šã«ãæäžéããšã«ãŸãšããŠç€ºãã
ãè¡šã
ãè¡šã
ãããã®ããŒã¿ããããããã¯ãããã¢ãžãèª
çºäœã«ãªãŠã è¡çã®å埩ã«ããã€ãªã¢ãã€ã©ããª
ãã€ã®æé©ãªããªã¢ã ãã¬ã³ãæå¹ã§ããããšã
確èªãããããã®å¹æã¯ãè©Šéšããæäžéã®ãã¡
é«ãç¯å²ã§ç¹ã«å€§ãããçŽ75mgã®ããªã¢ã ãã¬ã³
ïŒ50mgã®ãããã¯ãããã¢ãžããšå ±ã«ïŒã®æäžæ°Ž
æºã§ãæ倧ã«è¿ãå¿çãèªããããã ãããã®çµæã第衚åã³ç¬¬â衚ã«ç€ºãã
ããŒã¿ãšæ¯èŒããããšã«ãã€ãŠãçŸåšåžè²©ãããŠ
ããåŸæ¥ã®çµæç©ãæ¬çºæã®çµæç©ã«ãã€ãŠçã
ãã¬ãã«ãšã¯ç°ãªããäœã«ãªãŠã è¡çç¶ã®æ²»çå
ã¯å埩ã«é¢ããŠããªã¢ã ãã¬ã³ã®é©åãªãã€ãªã¢
ãã€ã©ããªãã€ãçããªãããšãå€ãã äŸ ïŒ æŽã«ãæ¬çºæã«ãã€ãŠæäŸãããçµæç©ã®å掻
æ§æåã®åäžããæé©ãªãã€ãªã¢ãã€ã©ããªãã€
ã確èªãããããæ¬çºæã«ããããªã¢ã ãã¬ã³75
mgåã³ãããã¯ãããã¢ãžã50mgãå«ãé å€ã補
é ããããããã®é å€ã«ã€ããŠé µçŽ ãå«ãŸãªãPH
1.2ã®äººå·¥è液900mläžã§USPããã«æ³ã䜿çšããŠ
37âã§50RPMã§æº¶è§£é床ã®ç 究ãè¡ãªã€ããã
ã®è©Šéšã¯ãç±³åœè¬å±æ¹XIXã第ïŒè¿œè£ã®æº¶è§£ã
æ¹æ³ã®é ãåœæ°å»è¬åéXIVã194é ïŒ1978幎
ïŒæ31æ¥å ¬åžïŒã«èšèŒãããŠããããã®ãããªæº¶
解çµæã¯ãããªã¢ã ãã¬ã³âãããã¯ãããã¢ãž
ãè€åçæç©ã«é¢ããŠFDAã«ãã€ãŠå©çšããã
ãã·ã€ãŒïŒV.P.ShahïŒããã©ãµãïŒF.K.PrasadïŒã
ãªã³ïŒJ.LinïŒãã¯ãããïŒG.KnappïŒåã³ã«ãã
ïŒB.E.CabanaïŒã«ããã1982幎11æ14ã18æ¥ã®ã¢
ã¡ãªã«è¬åŠåäŒäŒè°ïŒNational Meeting of the
American Pharmaceutical AssociationïŒãè¬åŠ
éšäŒïŒAcademy of pharmaceutical Sciences
DivisionïŒã§çºè¡šãããæè¿ã®è«æïŒãã€ãªãã¢
ãŒãã·ãŠãŒãã€ã¯ã¹ã»ã©ãã©ããªã€
ïŒBiopharmaceutics LaboratoryïŒãã30ååŸåã³
60ååŸã®ãã®è©Šéšã®çµæã第衚ã«ç€ºããæ¯èŒã®
ãããçŸåšåžè²©ãããŠããåŸæ¥ã®ïŒ50ïŒ25ïŒã«ã
ã»ã«ãçšããŠåŸããã溶解çµæã第衚ã«ç€ºãã
æ¬çºæã«ãã補é ãã補åã§ã¯ãããªã¢ã ãã¬ã³
ã®æº¶è§£é床åã³ãããã¯ãããã¢ãžãã®æº¶è§£é床
ã極ããŠé«ãããšãå€ãã
çºäœã«ãªãŠã è¡çã®å埩ã«ããã€ãªã¢ãã€ã©ããª
ãã€ã®æé©ãªããªã¢ã ãã¬ã³ãæå¹ã§ããããšã
確èªãããããã®å¹æã¯ãè©Šéšããæäžéã®ãã¡
é«ãç¯å²ã§ç¹ã«å€§ãããçŽ75mgã®ããªã¢ã ãã¬ã³
ïŒ50mgã®ãããã¯ãããã¢ãžããšå ±ã«ïŒã®æäžæ°Ž
æºã§ãæ倧ã«è¿ãå¿çãèªããããã ãããã®çµæã第衚åã³ç¬¬â衚ã«ç€ºãã
ããŒã¿ãšæ¯èŒããããšã«ãã€ãŠãçŸåšåžè²©ãããŠ
ããåŸæ¥ã®çµæç©ãæ¬çºæã®çµæç©ã«ãã€ãŠçã
ãã¬ãã«ãšã¯ç°ãªããäœã«ãªãŠã è¡çç¶ã®æ²»çå
ã¯å埩ã«é¢ããŠããªã¢ã ãã¬ã³ã®é©åãªãã€ãªã¢
ãã€ã©ããªãã€ãçããªãããšãå€ãã äŸ ïŒ æŽã«ãæ¬çºæã«ãã€ãŠæäŸãããçµæç©ã®å掻
æ§æåã®åäžããæé©ãªãã€ãªã¢ãã€ã©ããªãã€
ã確èªãããããæ¬çºæã«ããããªã¢ã ãã¬ã³75
mgåã³ãããã¯ãããã¢ãžã50mgãå«ãé å€ã補
é ããããããã®é å€ã«ã€ããŠé µçŽ ãå«ãŸãªãPH
1.2ã®äººå·¥è液900mläžã§USPããã«æ³ã䜿çšããŠ
37âã§50RPMã§æº¶è§£é床ã®ç 究ãè¡ãªã€ããã
ã®è©Šéšã¯ãç±³åœè¬å±æ¹XIXã第ïŒè¿œè£ã®æº¶è§£ã
æ¹æ³ã®é ãåœæ°å»è¬åéXIVã194é ïŒ1978幎
ïŒæ31æ¥å ¬åžïŒã«èšèŒãããŠããããã®ãããªæº¶
解çµæã¯ãããªã¢ã ãã¬ã³âãããã¯ãããã¢ãž
ãè€åçæç©ã«é¢ããŠFDAã«ãã€ãŠå©çšããã
ãã·ã€ãŒïŒV.P.ShahïŒããã©ãµãïŒF.K.PrasadïŒã
ãªã³ïŒJ.LinïŒãã¯ãããïŒG.KnappïŒåã³ã«ãã
ïŒB.E.CabanaïŒã«ããã1982幎11æ14ã18æ¥ã®ã¢
ã¡ãªã«è¬åŠåäŒäŒè°ïŒNational Meeting of the
American Pharmaceutical AssociationïŒãè¬åŠ
éšäŒïŒAcademy of pharmaceutical Sciences
DivisionïŒã§çºè¡šãããæè¿ã®è«æïŒãã€ãªãã¢
ãŒãã·ãŠãŒãã€ã¯ã¹ã»ã©ãã©ããªã€
ïŒBiopharmaceutics LaboratoryïŒãã30ååŸåã³
60ååŸã®ãã®è©Šéšã®çµæã第衚ã«ç€ºããæ¯èŒã®
ãããçŸåšåžè²©ãããŠããåŸæ¥ã®ïŒ50ïŒ25ïŒã«ã
ã»ã«ãçšããŠåŸããã溶解çµæã第衚ã«ç€ºãã
æ¬çºæã«ãã補é ãã補åã§ã¯ãããªã¢ã ãã¬ã³
ã®æº¶è§£é床åã³ãããã¯ãããã¢ãžãã®æº¶è§£é床
ã極ããŠé«ãããšãå€ãã
ãè¡šã
ãè¡šã
çç©å¹æã®é«ãäžåéåºäœè£œå€äžã«ãããã¯ã
ããã¢ãžãåã³ããªã¢ã ãã¬ã³ãäžç·ã«é åãã
ãšããåé¡ãèªèãããé·å¹Žæ®ã€ãŠããŠããæ¬çº
æã«ãã€ãŠåŸãããé²æ©åã³å¯äžã¯ãæ¬çºæ以å
ã«ã¯åœæ¥è ã«ã¯èŠãåºãããªãã€ãã åŸã€ãŠãæ¬çºæã¯ãäžææãªãããã¯ãããã¢
ãžãâèªçºäœã«ãªãŠã è¡äœçšãæå¶åã¯å埩ãã
䜿çšããªããã°ãªããªãããªã¢ã ãã¬ã³ã®éãæ
å°ã«ããªãããæå¹ãªå©å°¿âéå§äœçšãçããç¡
æ¯æ§å»è¬è€åçµæç©ã補é ããç¹ç°ãªæ¹æ³ãæäŸ
ãããã®ã§ããããã®ããšã¯ãã¹ãŠããããã¯ã
ããã¢ãžã³åã¯ããªã¢ã ãã¬ã³ã®åå³è£œå€ãšå®è³ª
ã«åçåã®ããããè¯å¥œãªãã€ãªã¢ãã€ã©ããªã
ã€ãçããããšã«ãã€ãŠéæãããã æ¬çºæã®ãã®ãããªçµæç©ãæäžããéã«ã¯ã
æ£è ã«ãïŒæ¥ã«æ¶è²»ãããããªã¢ã ãã¬ã³ã®ç·é
ãçŽ150mgïŒæ¥ã®ææã®æé«é床ããå€ããªããŠ
ããïŒæ¥ã®æäžéã§çµæç©ãæäžããã®ãäžè¬ç
ã§ãããããªã¢ã ãã¬ã³ã®ïŒæ¥ã®æäžéã¯äžè¬ã«
çŽ37ã150mgã§ããã åèšã®å®æœäŸã¯ã奜ãŸãããããã¯ãããã¢ãž
ãæååã³ããªã¢ã ãã¬ã³æåãçšããŠæ¬çºæã®
å®æœã説æããããå¥ã®æåãçšããŠåãæäœã«
åŸãããšãã§ãããã®ã§ãããå³ã¡ãããªã¢ã ã
ã¬ã³ã®ä»£ããã«ãïŒïŒïŒïŒïŒâããªã¢ããâïŒâ
ïœâãã«ãªãããšãã«ãããªãžã³ãïŒïŒïŒïŒïŒâ
ããªã¢ãã³âïŒâïœâããªãã«ãªãã¡ãã«âããš
ãã«ãããªãžã³ãïŒïŒïŒïŒïŒâããªã¢ããâïŒâ
ïœâãšããã·ããšãã«ãããªãžã³ãïŒâãžã¡ãã«
ã¢ããâïŒïŒïŒâãã¹ã¡ãã«ã¢ããâïŒâããšã
ã«ãããªãžã³ãïŒïŒïŒïŒïŒâããªã¢ããâïŒâα
âããšãã«ãããªãžã³ãïŒïŒïŒïŒïŒâããªã¢ãã
âïŒâïœâã¡ãã«ããšãã«ãããªãžã³ãïŒïŒïŒâ
ãžã¢ããâïŒâãžã¡ãã«ã¢ããâïŒâããšãã«ã
ããªãžã³ãïŒïŒïŒïŒïŒâããªã¢ããâïŒâïœâã¡
ããã·âããšãã«ãããªãžã³ãïŒïŒïŒïŒïŒâããª
ã¢ããâïŒâïœâã¡ãã«ããšãã«ãããªãžã³ã䜿
çšããããšãã§ãããããªã¢ã ãã¬ã³åã³ä»ã®ã
ããªãžã³ã®ä»£è¬çæç©ãäŸãã°ããããã·ããªã¢
ã ãã¬ã³ç¡«é žãšã¹ãã«ã䜿çšããããšãã§ããã æ¬æ现æžã«ãããŠãçšèªãããªã¢ã ãã¬ã³â掻
æ§ãããªãžã³æåãã¯ããã®ãããªæåã®ïŒçš®ä»¥
äžãæå³ãããã®ãšããã æŽã«ããããã¯ãããã¢ãžãã®ä»£ãã«ãã¯ãã
ãã¢ãžãããã³ãžãããã«ã¡ãã¢ãžããããªã¯ã
ãã¡ãã¢ãžããããããã«ã¡ãã¢ãžãããã«ã¡ã
ã¢ãžããã¡ãã«ã¯ããã¢ãžããã¯ãã«ã¿ãªãã³å
ã¯ãã³ãºããªãžãã䜿çšããããšãã§ãããæ¬æ
现æžã«ãããŠãçšèªããããã¯ãããã¢ãžãâ掻
æ§ãã³ãŸãã¢ãžã¢ãžãæåãã¯ãããã®æåã®ïŒ
皮以äžãæå³ãããã®ãšããã æŽã«åºãèšãã°ãæ¬çºæã¯ãå°ãªããšãïŒçš®ã®
å»è¬æŽ»æ§æåãå«ã¿ããã®ãã¡å°ãªããšãïŒçš®ã¯
ä»æ¹ããçžå¯Ÿçã«çæ°Žæ§ã§ããã掻æ§æåãçµã¿
åãããšãã«ãå掻æ§æåã®ãã€ãªã¢ãã€ã©ããª
ãã€ãåäžããŠããåºäœå»è¬çµæç©ã®äžè¬ç補é
æè¡ãæäŸãããã®ã§ãããå³ã¡ãåãåºæ¬æäœ
ã䜿çšããŠç¹ã«äžã«è¿°ã¹ããã®ä»¥å€ã®æŽ»æ§æåã®
çµã¿åãã䜿çšããããšãã§ããæ¬çºæã¯ããã®
ãããªæåã®äžæ¹ãä»æ¹ããçžå¯Ÿçã«çæ°Žæ§ã§ã
ããäž¡æ¹ã®æŽ»æ§æåã«é¢ããŠé«ããã€ãªã¢ãã€ã©
ããªãã€ãæãŸããå Žåã«ãç¹ã«æçšã§ãããäž
è¬ã«ããã®ãããªçµæç©ã«ãããŠããã®ãããªå»
è¬æŽ»æ§æåã®é©åãªééæ¯ã¯ãäŸãã°åèšã®ãã
ãªæçãªèšåºè©Šéšåã³å®éšå®€è©Šéšãåã¯åœæ¥è ã®
éžæããä»ã®é©åãªè©Šéšã«ãã€ãŠå掻æ§æåã®å¹
æãæ倧ã«ãªãããã«éžæããã 説æã®ãããæ¬çºæã®ç¹å¥ã®å®æœæ ãèšèŒãã
ããç¹èš±è«æ±ã®ç¯å²ã«èšèŒããæ¬çºæã®ç¯å²ãéž
è±ããããšãªãã现éšãå€æ§ã«å€åãããããš
ã¯ãåœæ¥è ã«ã¯æããã§ããã
ããã¢ãžãåã³ããªã¢ã ãã¬ã³ãäžç·ã«é åãã
ãšããåé¡ãèªèãããé·å¹Žæ®ã€ãŠããŠããæ¬çº
æã«ãã€ãŠåŸãããé²æ©åã³å¯äžã¯ãæ¬çºæ以å
ã«ã¯åœæ¥è ã«ã¯èŠãåºãããªãã€ãã åŸã€ãŠãæ¬çºæã¯ãäžææãªãããã¯ãããã¢
ãžãâèªçºäœã«ãªãŠã è¡äœçšãæå¶åã¯å埩ãã
䜿çšããªããã°ãªããªãããªã¢ã ãã¬ã³ã®éãæ
å°ã«ããªãããæå¹ãªå©å°¿âéå§äœçšãçããç¡
æ¯æ§å»è¬è€åçµæç©ã補é ããç¹ç°ãªæ¹æ³ãæäŸ
ãããã®ã§ããããã®ããšã¯ãã¹ãŠããããã¯ã
ããã¢ãžã³åã¯ããªã¢ã ãã¬ã³ã®åå³è£œå€ãšå®è³ª
ã«åçåã®ããããè¯å¥œãªãã€ãªã¢ãã€ã©ããªã
ã€ãçããããšã«ãã€ãŠéæãããã æ¬çºæã®ãã®ãããªçµæç©ãæäžããéã«ã¯ã
æ£è ã«ãïŒæ¥ã«æ¶è²»ãããããªã¢ã ãã¬ã³ã®ç·é
ãçŽ150mgïŒæ¥ã®ææã®æé«é床ããå€ããªããŠ
ããïŒæ¥ã®æäžéã§çµæç©ãæäžããã®ãäžè¬ç
ã§ãããããªã¢ã ãã¬ã³ã®ïŒæ¥ã®æäžéã¯äžè¬ã«
çŽ37ã150mgã§ããã åèšã®å®æœäŸã¯ã奜ãŸãããããã¯ãããã¢ãž
ãæååã³ããªã¢ã ãã¬ã³æåãçšããŠæ¬çºæã®
å®æœã説æããããå¥ã®æåãçšããŠåãæäœã«
åŸãããšãã§ãããã®ã§ãããå³ã¡ãããªã¢ã ã
ã¬ã³ã®ä»£ããã«ãïŒïŒïŒïŒïŒâããªã¢ããâïŒâ
ïœâãã«ãªãããšãã«ãããªãžã³ãïŒïŒïŒïŒïŒâ
ããªã¢ãã³âïŒâïœâããªãã«ãªãã¡ãã«âããš
ãã«ãããªãžã³ãïŒïŒïŒïŒïŒâããªã¢ããâïŒâ
ïœâãšããã·ããšãã«ãããªãžã³ãïŒâãžã¡ãã«
ã¢ããâïŒïŒïŒâãã¹ã¡ãã«ã¢ããâïŒâããšã
ã«ãããªãžã³ãïŒïŒïŒïŒïŒâããªã¢ããâïŒâα
âããšãã«ãããªãžã³ãïŒïŒïŒïŒïŒâããªã¢ãã
âïŒâïœâã¡ãã«ããšãã«ãããªãžã³ãïŒïŒïŒâ
ãžã¢ããâïŒâãžã¡ãã«ã¢ããâïŒâããšãã«ã
ããªãžã³ãïŒïŒïŒïŒïŒâããªã¢ããâïŒâïœâã¡
ããã·âããšãã«ãããªãžã³ãïŒïŒïŒïŒïŒâããª
ã¢ããâïŒâïœâã¡ãã«ããšãã«ãããªãžã³ã䜿
çšããããšãã§ãããããªã¢ã ãã¬ã³åã³ä»ã®ã
ããªãžã³ã®ä»£è¬çæç©ãäŸãã°ããããã·ããªã¢
ã ãã¬ã³ç¡«é žãšã¹ãã«ã䜿çšããããšãã§ããã æ¬æ现æžã«ãããŠãçšèªãããªã¢ã ãã¬ã³â掻
æ§ãããªãžã³æåãã¯ããã®ãããªæåã®ïŒçš®ä»¥
äžãæå³ãããã®ãšããã æŽã«ããããã¯ãããã¢ãžãã®ä»£ãã«ãã¯ãã
ãã¢ãžãããã³ãžãããã«ã¡ãã¢ãžããããªã¯ã
ãã¡ãã¢ãžããããããã«ã¡ãã¢ãžãããã«ã¡ã
ã¢ãžããã¡ãã«ã¯ããã¢ãžããã¯ãã«ã¿ãªãã³å
ã¯ãã³ãºããªãžãã䜿çšããããšãã§ãããæ¬æ
现æžã«ãããŠãçšèªããããã¯ãããã¢ãžãâ掻
æ§ãã³ãŸãã¢ãžã¢ãžãæåãã¯ãããã®æåã®ïŒ
皮以äžãæå³ãããã®ãšããã æŽã«åºãèšãã°ãæ¬çºæã¯ãå°ãªããšãïŒçš®ã®
å»è¬æŽ»æ§æåãå«ã¿ããã®ãã¡å°ãªããšãïŒçš®ã¯
ä»æ¹ããçžå¯Ÿçã«çæ°Žæ§ã§ããã掻æ§æåãçµã¿
åãããšãã«ãå掻æ§æåã®ãã€ãªã¢ãã€ã©ããª
ãã€ãåäžããŠããåºäœå»è¬çµæç©ã®äžè¬ç補é
æè¡ãæäŸãããã®ã§ãããå³ã¡ãåãåºæ¬æäœ
ã䜿çšããŠç¹ã«äžã«è¿°ã¹ããã®ä»¥å€ã®æŽ»æ§æåã®
çµã¿åãã䜿çšããããšãã§ããæ¬çºæã¯ããã®
ãããªæåã®äžæ¹ãä»æ¹ããçžå¯Ÿçã«çæ°Žæ§ã§ã
ããäž¡æ¹ã®æŽ»æ§æåã«é¢ããŠé«ããã€ãªã¢ãã€ã©
ããªãã€ãæãŸããå Žåã«ãç¹ã«æçšã§ãããäž
è¬ã«ããã®ãããªçµæç©ã«ãããŠããã®ãããªå»
è¬æŽ»æ§æåã®é©åãªééæ¯ã¯ãäŸãã°åèšã®ãã
ãªæçãªèšåºè©Šéšåã³å®éšå®€è©Šéšãåã¯åœæ¥è ã®
éžæããä»ã®é©åãªè©Šéšã«ãã€ãŠå掻æ§æåã®å¹
æãæ倧ã«ãªãããã«éžæããã 説æã®ãããæ¬çºæã®ç¹å¥ã®å®æœæ ãèšèŒãã
ããç¹èš±è«æ±ã®ç¯å²ã«èšèŒããæ¬çºæã®ç¯å²ãéž
è±ããããšãªãã现éšãå€æ§ã«å€åãããããš
ã¯ãåœæ¥è ã«ã¯æããã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ (a)å°ãªããšãïŒçš®ã®çŽ°åãããè¬åŠçã«èš±å®¹
ãããäžæŽ»æ§æåãšæ··åããŠããªã¢ã ãã¬ã³æŽ»æ§
ãããªãžã³æåã®çŽ°åãããç²åãå«ããå¥åã«
圢æããããã°ãã°ãã®ç¬¬äžé¡ç²ãåã³(b)å°ãªã
ãšãïŒçš®ã®çŽ°åãããè¬åŠçã«èš±å®¹ãããäžæŽ»æ§
æåãšæ··åããŠãããã¯ãããã¢ãžã掻æ§ãã³ãŸ
ãã¢ãžã¢ãžãæåã®çŽ°åãããç²åãå«ããå¥å
ã«åœ¢æããããã°ãã°ãã®ç¬¬äºé¡ç²ãå«ãã§æ
ãããã³ãŸãã¢ãžã¢ãžãã«ãã€ãŠèªçºãããäœã«
ãªãŠã è¡çç¶ãæå¶ããã®ã«æå¹ãªãããªãžã³ã®
ãã€ãªã¢ãã€ã©ããªãã€ãçããééæ¯ã§åèšã
ããªãžã³æåãšåèšãã³ãŸãã¢ãžã¢ãžãæåãšã
å«æããããã«åèšç¬¬äžé¡ç²ãšç¬¬äºé¡ç²ãšãæ··å
ãããŠãããè¬åŠçã«æå¹ãªæé«è¡å§ãå©å°¿åã³
æäœã«ãªãŠã è¡äœçšã䜵æããé¡ç²ç¶äžåäžçµæ
ç©ã ïŒ åèšã®çŽ°åããããè¬åŠçã«äžæŽ»æ§ãªäžæŽ»æ§
æåããŠã€ããã³ã°å€ã厩å£å€ãè¡šé¢æŽ»æ§å€ãæ»
æ²¢å€åã³å§çž®å©å€ãå«ãçš®é¡ã®ãã®ã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ åèšãããªãžã³æåãããªã¢ã ãã¬ã³ã§ã
ããåèšãã³ãŸãã¢ãžã¢ãžãæåããããã¯ãã
ãã¢ãžãã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæ
ç©ã ïŒ ããªã¢ã ãã¬ã³ãšãããã¯ãããã¢ãžã³ã®é
éæ¯ãçŽ1.5ïŒïŒã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èš
èŒã®çµæç©ã ïŒ äžåéã«ãã»ã«å€ãšããŠåŠæ¹ãããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ ç¬¬äžåã³ç¬¬äºé¡ç²ãšæ··åããŠå°ãªããšãïŒçš®
ã®æ»æ²¢å€ãå«ãäžåéé å€ãšããŠåŠæ¹ãããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ é å€ãšããŠè£œå€åãããŠãããåèšã®ç¬¬äžå
ã³ç¬¬äºã®åé¡ç²ãšæ··åããŠæ»æ²¢å€ãé å€äžã«å«ã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ åèšã®çŽ°åãããç²åœ¢ãããã®å°ãªããšã95
ïŒ ã100ã¡ãã·ãŠã®ç¯©ãééããçšåºŠã®ç²åŸç¯å²
ãæããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ åèšé¡ç²ããïŒmmãã倧ãããã®ãïŒïŒ 以äž
ã§ã0.075mmããå°ãããã®ã20ïŒ ä»¥äžã§ããç²
åŸç¯å²ãæããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæ
ç©ã ïŒïŒ ããªã¢ã ãã¬ã³æŽ»æ§ãããªãžã³æåã®çŽ°å
ãããç²åã现åãããè¬åŠçã«èš±å®¹ãããäžæŽ»
æ§æåã®å°ãªããšãïŒçš®ãšæ··åããŠç¬¬äžã®æ··åç©
ãäœãããã®ç¬¬äžã®æ··åç©ãé ç²ããŠåèšã®ç¬¬äž
æ··åç©ã®ç²åã®åäžæ··åç©ããæã第äžã®é¡ç²ã
圢æããå·¥çšïŒ å¥åã«ããããã¯ãããã¢ãžã掻æ§ãã³ãŸãã¢
ãžã¢ãžãæåã®çŽ°åãããç²åã现åãããè¬åŠ
çã«èš±å®¹ãããäžæŽ»æ§æåã®å°ãªããšãïŒçš®ãšæ··
åããŠç¬¬äºã®æ··åç©ãäœãããã®ç¬¬äºã®æ··åç©ã
é ç²ããŠåèšã®ç¬¬äºæ··åç©ã®ç²åã®åäžæ··åç©ã
ãæã第äºã®é¡ç²ã圢æããå·¥çšïŒäžŠã³ã« ããããŠåœ¢æãã第äžåã³ç¬¬äºã®é¡ç²ãã第äž
åã³ç¬¬äºã®é¡ç²ã®ããããã®ç¬èªæ§ãä¿æããªã
ããåèšãã³ãŸãã¢ãžã¢ãžãæåã®æäžã«ãã€ãŠ
èµ·ããäœã«ãªãŠã è¡çãæå¶ããã®ã«æå¹ãªåèš
ãããªãžã³æåã®ãã€ãªã¢ãã€ã©ããªãã€ãŒãç
ããééæ¯ã§åèšãããªãžã³æåãšåèšãã³ãŸã
ã¢ãžã¢ãžãæåãšãæçµçµæç©ãå«æãããããª
çžå¯Ÿéã§ãç©ççã«æ··åããå·¥çšïŒ ãå«ãã§æããå»è¬ãšããŠæå¹ãªå©å°¿ãæäœã«ãª
ãŠã è¡åã³æé«è¡å§æŽ»æ§ã䜵æããé¡ç²äžåäžçµ
æç©ã®è£œé æ¹æ³ã ïŒïŒ åèšãããªãžã³æåãããªã¢ã ãã¬ã³ã§ã
ããåèšãã³ãŸãã¢ãžã¢ãžãæåããããã¯ãã
ãã¢ãžãã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æ¹
æ³ã ïŒïŒ ããªã¢ã ãã¬ã³ïŒãããã¯ãããã¢ãžãã®
ééæ¯ã1.25ã1.75ïŒïŒã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒïŒé èšèŒã®æ¹æ³ã ïŒïŒ åèšééæ¯ãçŽ1.5ïŒïŒã§ããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒïŒé èšèŒã®æ¹æ³ã ïŒïŒ åèšã®çŽ°åãããããªã¢ã ãã¬ã³ç²åãã
ã®å°ãªããšã95ïŒ ã200ã¡ãã·ãŠã®ç¯©ãééãã
ç²åŸç¯å²ãæããåèšã®çŽ°åããããããã¯ãã
ãã¢ãžãç²åããã®95ïŒ ã100ã¡ãã·ãŠã®ç¯©ãé
éããç²åŸç¯å²ãæããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé
èšèŒã®æ¹æ³ã ïŒïŒ åèšé¡ç²ããïŒmmãã倧ãããã®ãïŒïŒ 以
äžã§ã0.075mmããå°ãããã®ã20ïŒ ä»¥äžã§ãã
ç²åŸç¯å²ãæããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®
æ¹æ³ã ïŒïŒ åèšé¡ç²ãã1.5mmãè¶ãããã®ãïŒïŒ 以
äžã§ããç²åŸç¯å²ãæããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒ
é èšèŒã®æ¹æ³ã ïŒïŒ åèšã®è¬åŠçã«èš±å®¹ãããäžæŽ»æ§æåããŠ
ã€ããã³ã°å€ã厩å£å€ãè¡šé¢æŽ»æ§å€ãæ»æ²¢å€åã³
å§çž®å©å€ãå«ãçš®é¡ã®ãã®ã§ããç¹èš±è«æ±ã®ç¯å²
第ïŒïŒé èšèŒã®æ¹æ³ã ïŒïŒ åèšãŠã€ããã³ã°å€ãçŽ200ã¡ãã·ãŠã®ç¯©
ãééãããã倧ããé·ææ¹åã®å¯žæ³ãæããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æ¹æ³ã
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40227982A | 1982-07-27 | 1982-07-27 | |
| US402279 | 1982-07-27 | ||
| US456311 | 1983-01-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5933213A JPS5933213A (ja) | 1984-02-23 |
| JPH0119364B2 true JPH0119364B2 (ja) | 1989-04-11 |
Family
ID=23591266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13530083A Granted JPS5933213A (ja) | 1982-07-27 | 1983-07-26 | å»è¬çµæç©åã³ãã®è£œé æ¹æ³ |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5933213A (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| JP4565456B2 (ja) * | 1999-11-02 | 2010-10-20 | å¡©é矩補è¬æ ªåŒäŒç€Ÿ | çè²é¡ç²ã®è²çŽ å®çæ³ |
| FR2857778B1 (fr) * | 2003-07-17 | 2006-02-03 | Commissariat Energie Atomique | Actionneur magnetique a levitation a temps de commutation et/ou courant d'actionnement reduits. |
| JP5459670B2 (ja) * | 2010-05-07 | 2014-04-02 | å¡©é矩補è¬æ ªåŒäŒç€Ÿ | çè²é¡ç²ã®è²çŽ å®çåå€ |
-
1983
- 1983-07-26 JP JP13530083A patent/JPS5933213A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5933213A (ja) | 1984-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0068191B1 (de) | Orale Dipyridamolformen | |
| ES2205000T3 (es) | Composicion farmaceutica que contiene irbesartan. | |
| EP0522128B1 (en) | Water-dispersible tablets | |
| EP0693281B1 (en) | Fluoxetine Pharmaceutical formulations | |
| DE60027464T2 (de) | Arzneizubereitungen mit zwei verschiedenen freisetzungsraten enthaltend einen cyclooxygenase-2 hemmer | |
| TWI245632B (en) | Solid oral dosage form comprising a combination of metformin and glibenclamide | |
| JPH07558B2 (ja) | ã¢ããã¢ãŒã«è£œå€ | |
| PL200957B1 (pl) | Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej | |
| EP0301006B1 (en) | Methylprednisolone/sodium carboxymethyl starch tablet composition | |
| US20040197402A1 (en) | Oxcarbazepine dosage forms | |
| KR20040079898A (ko) | ë©íží¬ë¥Žë¯Œ ë° êžëŠ¬ë²€íŽëŒë¯žë륌 í¬íšíë ì 2í ë¹ëšë³ì¹ë£ì© ìœì íì ì¡°ì±ë¬Œ | |
| PL190988B1 (pl) | Preparat tabletki lub kapsuÅki do poÅykania i sposób ich wytwarzania | |
| US4444769A (en) | Antihypertensive diuretic combination composition and associated method | |
| US4526777A (en) | Pharmaceutical combination composition and associated method | |
| US20020028248A1 (en) | Rapid-release microdispersible ecadotril preparation | |
| JP2007513975A (ja) | åŸæŸæ§ãã«ã»ããå€åœ¢ | |
| US4547498A (en) | Pharmaceutical combination composition and associated method | |
| JPH0119364B2 (ja) | ||
| JP2000516601A (ja) | 氎溶æ§ååç©åã³ã»ã«ããŒã¹ãå«æããç²ç¶ç© | |
| US4804540A (en) | Process for preparing the combination products of triamterene and hydrochlorothiazide | |
| JP2015537013A (ja) | é厩æ§é å€ | |
| EP0207405B1 (en) | Method for making pharmaceutical combination composition in granularly heterogenous solid unit dosage form with enhanced bioavailability | |
| CN107510696A (zh) | çšäºæ²»çéé 粟æ§èèªèçè¯ç©ç»åç© | |
| JP2003221329A (ja) | åå²éã¢ããé žãå«æãããã©ã€ã·ãããå€ | |
| EP1711182A1 (en) | Oral cyclodextrin complexes of antituberculosis drugs |